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Abstract
CD19 Chimeric Antigen Receptor (CAR) therapy represents a breakthrough in the
treatment of relapsed/refractory acute lymphoblastic leukaemia and early-phase
clinical trials with CAR-modified-T cells have shown unprecedented responses.
A CAR is a recombinant receptor that combines a single chain variable fragment
(scFv) against a tumour-associated antigen and an intracellular activation domain
of the T cell receptor (TCR), recognizing membrane-bound antigen, typically with
a higher affinity compared to TCR-pMHC affinity. We compared the influences
of differences in on- and off-rates underlying the binding kinetics of CD19 CARs
on downstream CAR T cell responses and constructed a novel CAR derived from
the CAT hybridoma demonstrating a lower affinity as a result of a greater off-rate,
whilst maintaining an on-rate nearly identical to FMC63, the scFv most-used in
clinical trials. Using in vitro pre-clinical models we demonstrated that CAT-CAR+ T
cells showed increased proliferation, higher cytotoxic responses, and increased cy-
tokine production, as well as a greater number of interactions between CAT-CAR+
T cells and target cells and a greater motility in comparison to FMC63. In vivo
CAT-CAR+ T cells showed an enhanced ability to clear disease, proliferate and pro-
duce cytokines, displaying markers characteristic for improved T cell fitness. We
believe that, analogous to the natural TCR, a lower overall binding affinity might
be mitigated by a relatively faster off-rate in the setting of a constant on-rate and
propose that this may enhance CAR T cell function through serial triggering, where
increased target:effector interaction time, may lead to exhaustion and activation in-
duced cell death. These data have important implications for the development of
future CARs.
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Chapter 1
Introduction
“Natural forces within us are the true healers of disease”
–Hippocrates–
1.1 Acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is generally classified into B-lymphoblastic
and T-lymphoblastic leukaemias, and further subclassified according to specific
genetic abnormalities. Within the context of this thesis, I will focus on B-
lymphoblastic leukaemias (B-ALL).
B-ALL is seen in both children and adults, but is the commonest childhood
cancer, comprising approximately 30% of all childhood malignancies [1]. with a
peak incidence between ages 2 and 5 years. The pathogenesis of ALL is believed to
be multi-factorial, including exogenous or endogenous exposures, genetic suscepti-
bility, and chance [2]. Predictions of prognosis depend on several factors including
initial white blood cell (WBC) count, age, cytogenetic abnormalities, immunologic
subtype - including early B cell, mature B cell and T cell lineage - and early re-
sponse to cytoreductive therapy.
1.1.1 Genetic profile risk stratification
Next generation sequencing and microarray analysis have provided considerable
understanding and insights into the pathogenesis and clinical course of ALL. Most
ALL genomes contain sequence and structural DNA alterations involving coding
genes, as well as alterations of noncoding elements such as noncoding RNAs and
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enhancer elements[3]. Chromosomal alterations are characteristic for ALL. Fre-
quencies of distinct genetic profiles and their association with outcome are summa-
rized in table 1.1
1.1.2 Treatment
Current treatment regimens utilise risk based therapy to avoid over- or under-
treatment of individual patients and include chemotherapy, radiation therapy and
bone marrow transplantation [4], resulting in 5-year event-free survival rates that ex-
ceed 85% in children, as illustrated in figure 1.1. However, therapeutic failure lead-
ing to relapse has been associated with a poor outcome, and ALL remains the lead-
ing cause of cancer-related death in children and young adults [5–7]. The largely
non-specific nature of these treatments leads to acute toxic side effects, resulting in
severe short- and long term co-morbidities, such as infertility and secondary ma-
lignancies, with a 10-year cumulative risk ranging from 3.2% to 9.9% [8]. This
underscores the need to further improve survival whilst reducing side-effects.
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Table 1.1: Frequencies and related risk stratification of genetic alterations in paediatric pre-
B ALL
Adapted from Hunger and Mullighan [3]
Subtype Prevalence % Comments
Hyperdiploidy with > 50 chromosomes 20-30 Excellent prognosis
Hyperdiploidy with < 44 chromosomes 2-3 Poor prognosis; high frequency of Ras path-
way and Ikaros gene family mutations
t(12;21)(p13;q22) translocation encoding
ETV6-RUNX1
15-25 Excellent prognosis
t(1;19)(q23;p13) translocation encoding
TCF3-PBX1
2-6 Increased incidence in African-Americans;
generally excellent prognosis; association
with CNS relapse
t(9;22)(q34;q11.2) translocation encoding
BCR-ABL1
2-4 Historically poor outcome; improved with
addition of tyrosine kinase inhibitors (TKI)
Ph-like ALL 10-15 Multiple kinase-activating lesions; associ-
ated with older age, elevated white blood
cell count, and IKZF1 alteration; potentially
amenable to TKI therapy
t(4;11)(q21;q23) translocation encoding
MLL-AF4 fusion
1-2 Common in infant ALL (especially age <6
mo); poor prognosis
t(8;14)(q24;q32), t(2;8)(q12;q24),
t(2;8)(q12;q24) encoding; MYC rear-
rangement
2 Favourable prognosis with short-term high-
dose chemotherapy
CRLF2 rearrangement (IGH-CRLF2;
P2RY8-CRLF2)
5-7 Common in Down syndrome and Ph-like
ALL (≈ 50% each); associated with IKZF1
deletion and/or mutation and JAK1/2 muta-
tion and poor prognosis in nonDown syn-
dromeassociated ALL
ERG-dysregulated ALL ≈ 7 Distinct gene expression profile; the major-
ity have focal ERG deletions and favourable
outcome despite IKZF1 alterations
PAX5 rearrangement ≈ 2 Multiple partners, commonly from dic(7;9),
dic(9;12), and dic(9;20)
iAMP21 ≈ 2 Complex structural alterations of chro-
mosome 21; rarely associated with a
constitutional Robertsonian translocation
rob(15;21)(q10;q10)c; poor prognosis
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Figure 1.1: Overall survival probability by treatment era
Patients enrolled onto Childrens Oncology Group trials in 1990-1994, 1995-1999, and 2000-2005
Source: [9]
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1.2 Adaptive immunity: focus on T cells
The human immune system has evolved into a powerful highly sophisticated de-
fence mechanism, equipped with innate and adaptive arms to eliminate a wide va-
riety of pathogens. A fundamental feature of the immune system is its ability to
distinguish between structural aspects of a pathogen (non-self) and its host tissue
(self), which is carefully confined to limit toxicity to the host. The innate effec-
tor cells of the immune system specialise in the recognition of pathogen-associated
molecular patterns (PAMPs), that are common on microbes or other host-invading
organisms and act rapidly upon encounter of its ligands [10]. The adaptive arm,
formed by B and T lymphocytes, is capable of undergoing somatic rearrangements
of antigen receptor genes, to generate an extensive repertoire of antigen-binding
molecules, which mediate humoral and cellular immune responses.
Random recombinations of gene elements encoding for the T cell receptor
(TCR) result in a diverse and polymorphic T-cell repertoire in the thymus. These so-
matic rearrangements result in an estimated 1018 TCRs of two types: αβ and γδ[11].
Intrathymic selection events then result in a repertoire of peripheral T-cell cells, that
are self-MHC restricted and not reactive to self-antigens.
1.2.1 T cell subsets
The majority of peripheral T cells in the circulation express the αβ TCR on their
surface, which is the main population of interest within the context of this thesis.
The TCR on the surface of each T cell recognizes its antigenic peptide bound to
major histocompatibility complex (MHC) molecules. The co-receptors CD8 and
CD4 bind a conserved membrane-proximal region on MHC-I and II respectively
[12]. They do not specifically facilitate adhesion and/or binding to MHC as its
major function, but rather play an important role in TCR signalling.
CD8+ cytotoxic T lymphocytes are, as their name reflects, capable of killing
infected or neoplastic cells. They harness an arsenal of cytotoxins, stored in special-
ized lytic granules and cytokines, such as Granzyme B, perforin, Tumour Necro-
sis Factor (TNF), Interferon-γ (IFN-γ), and macrophage inflammatory protein 1β
(MIP-1β), resulting in different anti-pathogenic effects.
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Helper T lymphocytes, or CD4+ T cells, can be divided into different subsets,
Th1, Th2, Th17 and Tfh, all conferring varying levels of protection against dif-
ferent pathogens and employing different helper responses. Specifically Th1 cells,
of importance when intracellular pathogens are targeted, activate macrophages and
release cytokines that attract macrophages to the site of infection [13].
1.2.2 TCR signalling
In addition to the variable α and β chains, composed of antigen-binding clonotypic
heterodimers with a single antigen-binding site, the TCR complex contains different
accessory chains. The CD3 complex is made up from CD3 γ, δ, ε and the ζ chain, a
largely intracytoplasmic homodimer [13]. These subunits are devoid of kinase ac-
tivity, but become phosphorylated and induce the assembly of a larger multiprotein
complex that is required to diversify the signal for the expression of multiple genes
[14]. Following TCR agonist stimulation, Src kinase family member Lck phospho-
rylates the tyrosine residues of immunoreceptor tyrosine-based activation motifs
(ITAMs) exposed on CD3, therein allowing Zap-70 recruitment, inducing the phos-
phorylation of the adaptor proteins LAT (linker for activation of T cells) and SLP76
(SRC homology 2 (SH2)-domain-containing leukocyte protein of 76 kDa) [14, 15].
This initiates a signalling cascade that leads to Ca2+ mobilization as well as to the
activation of the mitogen-activated protein kinase (MAPK) signalling pathway.
The magnitude of ITAM phosphorylation depends on the half-life of the
TCR/peptide MHC-complex (pMHC) interaction [16] and the presence of activated
Lck [14]. By delivering and sequestering Lck into the TCR-pMHC interaction,
CD4 and CD8 co-receptors optimize TCR signalling [15]. Lck must be anchored
to glycolipid-enriched membrane microdomains (GEMs) and its activity is regu-
lated by different elements including CD45, a transmembrane protein tyrosine phos-
phatase (PTP), regulating Lck independently of TCR engagement [14].
Cytoskeleton organization is tightly integrated with T cell activation and sig-
nalling. When T cells recognize APCs, the immunological synapse (IS) is formed.
The IS is the spatial frame of the TCR engaging with MHC and multiple accessory
molecules, promotes sustained T cell-APC interactions and serves as a platform
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for exchange of information between the two cells [17]. The adhesion and sig-
nal transduction depend on physical forces exerted by actin cytoskeletal dynamics.
IS-associated signalling molecules are physically linked to actin filaments. Con-
formational changes exerted by these forces are needed for full T cell activation
[18].
1.2.3 T cell receptor affinity
The binding and interaction of the TCR to a specific pMHC complex is pivotal in
regulating the activity and specificity of the T cell, setting off a cascade of intracel-
lular signals leading to cytokine production, proliferation and release of cytotoxic
granules. The extent of TCR mediated signal transduction in individual T cells (last-
ing for circa a few hours) and the duration of TCR/pMHC binding half-lives (lasting
a few seconds) are critical parameters in T cell activation [19]. The binding kinetics
of TCRs to pMHC complexes are determined by the association rate, on-rate, the
dissociation rate, off-rate, and their derivative, the dissociation constant (KD) that is
reciprocally related to the affinity of binding [20].
Affinity is a measure of the strength of the monomeric reversible binding be-
tween an epitope and an antibody’s antigen binding site or the TCR/pMHC com-
plex. High affinity antibodies will bind a greater amount of antigen in a shorter
period of time. The avidity is a measure of the overall strength, which is dependent
on the affinity, the structural arrangement and the valency of both the antibody and
the antigen. Viewed from the perspective of the TCR/pMHC, expression levels of
the antigen and TCR, and interactions of MHC with co-receptors CD4 or CD8 also
play a role. Interaction between the CD8 or CD4 co-receptor and MHC class I or
II stabilises T cell receptor-antigen complexes at the cell surface. Functional T cell
avidity is considered as the ability of T cells to respond to a given concentration of
cognate peptide antigen [21].
Both KD, the off-rate specifically, and the density of the target peptide pre-
sented on MHC influence T cell activation. TCR agonists for mature T cells are
of relatively low affinity (1-10 µM) and have fast off-rates [14]. The half-lives of
the interactions between a TCR and foreign-pMHC agonists are characteristically
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2-10 seconds [20]. T cells display an extraordinary sensitivity to low density anti-
gen. The sensitivity and polyfunctionality of T cells are controlled by TCR affinity,
where there is a threshold above which a higher affinity does not lead to a better
T cell function and very high affinity TCRs show cross-reactivity with self-derived
peptides [22]. These finding showed to be consistent among studies of various
groups. Irving et al observed that there were maximal T cell responses at lower
affinities, with a plateau of functional output between 1 µM and 5 µM [23]. Reduc-
ing the TCR affinity further however, has been demonstrated to affect different pa-
rameters of T cell activation such as the phosphorylation of CD3ζ, the activation of
the MAP kinase pathways and the ability to recruit cytotoxic granules [16, 24, 25].
A positive association has been described between TCR affinity and the degree of
polyfunctionality for CD8+ T cells within the earlier described window of TCR
affinity, which allows improved recognition of a tumour associated epitope in the
absence of apparent cross reactivity with other self-derived pMHC molecules [22].
Thus, within natural TCR responses, lower affinity in the setting of similar receptor
and antigen expression would be expected to result in lower functional avidity and
therefore reduced antigen-specific responses.
1.2.4 T cell activation
1.2.4.1 The 2-signal model of activation
The 2-signal model of T cell activation, distinguishes between the interaction be-
tween the TCR and the co-receptors with the pMHC complex, known as signal 1,
and secondary co-stimulation by antigen presenting cells (APCs), known as signal
2. As mentioned earlier, signal 1 leads to CD3 and ζ -chain ITAMs phosphorylation
by active Lck, resulting in the recruitment of Zap-70 that subsequently phosphory-
lates the key adapter protein linker for activation of T cells (LAT), leading to the
recruitment of downstream signalling proteins[27].
Signal 1 alone is not sufficient to activate a T cell and, when delivered solely,
could result in anergy [26]. For activation and proliferation to occur signal costimu-
lation is required, as provided by the 2 main receptor families; 1) the CD28 family,
including CD28, ICOS, interacting with CD80/CD86 and B7-H2, and 2) the TNF
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Figure 1.2: The 2-signal model of T cell activation
Source: [26]
Receptor Super Family (TNFRSF), including 4-1BB, CD27, CD40 and OX40, in-
teracting with 4-1BBL, CD70 (CD27L), CD40L and OX40L on antigen presenting
cells. These costimulatory signals have varying effects on T cell behaviour, such
as survival, effector function and formation of memory [26], as shown in figure
1.2. CD28 is thought to be of particular importance in early activation of naive T
cells, whereas the TNFRSF associated co-stimulatory domains are fundamental for
memory formation and persistence.
1.2.4.2 Kinetic models of T cell activation
The mechanisms underlying TCR sensitivity and specificity are not yet fully under-
stood. There are several models proposed to interpret how T cell signal amplifica-
tion takes place, following binding between TCR and pMHC. With a relatively low
affinity and generally a quick off-rate, T cells remain highly sensitive and specific
to an antigen [28].
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Kinetic Proofreading Model
The kinetic proofreading model proposes a signal is not immediately gener-
ated when a ligand binds to its receptor that utilizes a tyrosine kinase in signalling.
Binding of pMHC to TCR induces a series of biochemical reactions in the T cell.
If pMHC dissociates when these reactions are complete, the T cell receives a posi-
tive activation signal. However, dissociation of pMHC following completion of the
first reaction but prior to generation of the final products results in partial T cell
activation, which acts to suppress a positive response [29]. Short-lived nonspecific
complexes should usually fail to signal before dissociating [30]. However, exper-
imental evidence from Thomas et al contradicts this model, by exploring in detail
how TCR affinities spanning the natural range and extending 700-fold into the sup-
raphysiological range affected the kinetics and the sensitivity of primary human
CD8+ T cell responses. The functional analysis revealed that affinity maturation
beyond the physiological range accelerates CD8+ responses, but disrupts the serial
triggering that is needed to maximize recognition of low-density peptide ligands.
They showed that optimal peptide sensitivity was achieved with t1/2 of 9.3 seconds,
and that increasing the dissociation half time to 348, 1320, and 3120 seconds re-
sulted in a progressive loss of peptide sensitivity [31, 32]. Kalergis et al. show
that T cell activation can be impaired by mutations that either decrease or increase
the binding half-life of the TCR-pMHC interaction. Their data indicate that effi-
cient T cell activation occurs within an optimal dwell-time range of TCR-pMHC
interaction[33]. These studies both suggest that simply increasing immunoreceptor
interaction time does not result in a linear increase in T cell activation and suggest-
ing a more complex relationship between these parameters.
Serial triggering model
The serial triggering model was proposed as an alternative, suggesting there is
sequential binding of TCRs by a single pMHC, consistent with the short-lived na-
ture of the majority of TCR/pMHC interactions, thereby rendering T cells sensitive
for very low level of antigen [34]. However, it should be noted that this model was
based not on visualisation of TCR/pMHC interactions, but on the conjectural con-
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sequence, namely TCR down-regulation, as a read out of TCR occupancy. A more
recent study suggests, by using a single-molecule imaging technique, that even a
single-agonist pMHC can trigger cytokine production from some naive T cells [35].
Different studies elucidate the high sensitivity of T cells to antigenic stimu-
lation, as well as the importance of sustained signalling for T cell activation [28].
Figure 1.3 shows there is a defined window of half-life of TCR-ligand interactions
and number of TCRs engaged. While very short half-lives prevent productive TCR
triggering, half-lives exceeding the optimum interaction time decrease the efficiency
of TCR serial engagement. An interesting systematic analysis of T cell responses
by Lever et al. concluded that a peak amplitude of bell-shaped dose-response is in-
dependent of affinity, but that a low to intermediate affinity ligand produces largest
response at low doses pMHC [36].
Figure 1.3: A kinetic window defines strong TCR agonists
Source: [37]
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1.2.5 Cancer immunoediting
”It is by no means inconceivable that small accumulations of tumour cells may
develop and because of their possession of new antigenic potentialities provoke an
effective immunological reaction, with regression of the tumour and no clinical hint
of its existence.” In 1957 Sir Macfarlane Burnet instigated the concept that is now
known as cancer immunoediting [38].
Several decades following have taught us there are different aspects in which
the immune system plays a role in cancer biology. The importance of T cells in
immune surveillance has been demonstrated by an abundance of studies demon-
strating an improved survival of patients with a higher number tumour infiltrating
lymphocytes in solid tumours such as Non-Small Cell Lung Cancer, Breast Cancer,
Squamous Cell Carcinomas, Melanoma, and Brain Tumours [39–44], as well as the
increased incidence of tumours (particularly EBV associated lymphomas), in pa-
tients with primary immunodeficiency and those who are immunosuppressed after
organ transplant [45].
A study by Matsushita et al. showed that, by using a genomic approach, there
is a T cell dependent immunoselection process, leading to preferential outgrowth of
clones lacking immunodominant rejection antigens [46]. The clinical relevance of
these findings has been underlined by a study, showing that immunoediting occurs
as a consequence of immunotherapy in melanoma patients, revealing that in the
majority of patients that had relapsed, there was a loss of antigen that was initially
targeted [47, 48].
The cancer immunoediting hypothesis is hotly debated and has set out the prin-
ciples for understanding both the tumour directed response of the immune system
as well as its tumour sculpting actions [49]. Many labs have unambiguously shown
that immunity can induce cellular transformation, but also prevent or control tumour
growth and influence the immunogeneicity of the tumours [49]. These paradoxical
roles are determined by their temporal occurrence relative to tumour formation,
the different effectors of immunity involved, the transformational process and the
tumour associated antigens expressed on the transformed cell. The tumour immu-
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noediting hypothesis is composed of three phases; Elimination, Equilibrium and
Escape.
Elimination
In the elimination phase, the balance is towards anti-tumour immunity. Both
the innate and adaptive arms of the immune system together partake in the detection
and destruction of early tumour development, as shown in figure 1.4 [50].
Equilibrium
In the Equilibrium phase, the tumour is held in a state of dormancy. Genetic
and epigenetic changes result in tumour cell variants that exhibit antigen loss or per-
sistent tolerogenic antigen, and are therefore more resistant to immune recognition,
or the induction of immunosuppression by the expression of PD-L1 for example
[50].
Escape
In the Escape phase, clinical disease becomes apparent after the immune sys-
tem has failed to restrict tumour growth, through many different mechanisms. Im-
mune recognition is evaded by the tumour cells (by mechanisms such as the absence
of strong tumour antigens, or loss of MHC class I, class I-like, or co-stimulatory
molecules), tumour cells now express molecules of increased resistance (STAT-3),
survival (Bcl-2) and immunosuppression (PD-L1 for example) and the tumour mi-
croenvironment facilitates tumour growth by the expression of immunoregulatory
molecules and the secretion of immunosuppressive cytokines (IL-10, TGF-β). T
cells including regulatory T cells (Tregs) may also upregulate inhibitory receptors
such as PD-1, CTLA-4, TIM-3 and LAG-3 that suppresses anti-tumour immune
responses and favour tumour outgrowth [50].
The aim of cancer immunotherapy is to tip this balance towards the favourable
elimination phase, by employing the patient’s own immune system and re-eliciting
the anti-tumour response.
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Figure 1.4: Cancer immunoediting
In the immunoediting hypothesis, the tumour immune system balance shifts among tumour escape (to mutation-specific
antigens), equilibrium, and elimination.
Source: [50]
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1.3 Adoptive T cell therapy
As far back as the late 19th century, William B. Coley discovered that when tumours
were infected with a bacteria they shrank. Apparently, activation of the immune
system, caused by the infection, had a favourable outcome on the tumour. Coley’s
idea, far ahead of his time, lies at the basis of modern immunotherapy; targeted
tumour cell killing by use of the immune system’s cytotoxic mechanisms. Both
humoral and cellular components of the immune system are employed to enhance
the anti-tumour response, however only the latter will be discussed further. By
isolating and expanding tumour reactive T cells ex vivo before infusing them back
into a patient - known as adoptive T cell therapy (ACT) - one seeks to enhance
antitumour immunity by passive transfer.
ACT has several advantageous properties that make it effective for cancer ther-
apy: 1) The specificity of the T cell response allows potential differentiation be-
tween healthy and cancerous cells; 2) Following specific activation there is a robust
clonal expansion; 3) T cells are able to traffic to different sites where the antigen
of interest is expressed, and are thereby able to potentially target both the primary
tumour as well as metastases; 4) T cells are capable of a so called recall response
by antigen-specific memory T cells, resulting in ongoing tumour surveillance.
The adoptive T cell therapy field first started with using non-gene modified
T cells for the treatment of viral and non-viral malignancies. Several reports in
the early nineties described that by transfer of antigen-specific T cell clones reac-
tivation of CMV or EBV after haematopoietic stem cell transplantation (HSCT)
was prevented [51, 52]. Shortly thereafter, different groups started reporting about
adoptive T cell therapy in a non-viral malignant setting, demonstrating that tumour
infiltrating lymphocytes could mediate tumour regression in melanoma patients [53]
and that donor lymphocytes could successfully be applied as a treatment for chronic
myelogenous leukaemia relapsing after stem cell transplant [54].
One of the earliest reports of a T cell receptor (TCR) gene transfer using
gamma retroviral vector transduction described the introduction of a tumour associ-
ated antigen (TAA) specific TCR targeting MART-1 [55]. TCR gene transfer since
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then has been intensively studied and modification in the TCR α and β chain se-
quences and the introduction of a disulfide bond linking the constant domains have
reduced the risk of mispairing, which has proven to result in a lethal autoimmune
reaction in mice [56]. Most effective in avoiding mispairing has been the concomi-
tant knockdown of expression of the endogenous TCR by gene editing. TCR gene
transfer endows specificity against tumour associated antigens that can be derived
from the entire protein composition of tumour cells, including intracellular proteins
as well as specific mutant proteins that are restricted to tumour cells [57]. However,
there is a requirement for HLA-matching, owing to the restricted nature of TCR
function.
Investigating the modularity of the TCR structure, Eshhar et al. developed a
method where they coupled a single chain variable fragment (scFv) of an antibody
to CD3ζ of the TCR [58]. Initially this method was named a T-body, after the
combination of an antibody with the T cell activation. Since then the generally used
term is Chimeric Antigen Receptor (CAR).
Figure 1.5: Antibody structure and derived scFv
A. Full length IgG (˜150 kDa) B. scFv fragment (˜30 kDa) C.scFv-Fc (˜105 kDa)
.
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1.3.1 Chimeric Antigen Receptors
An scFv is an engineered antibody consisting of the immunoglobulin light chain
variable region (VL) and the heavy chain variable region (VH) linked by a peptide
linker sequence into a single polypeptide chain, retaining its specificity and affinity,
as illustrated in figure 1.5. A CAR is a recombinant receptor construct that combines
an scFv against a tumour-associated antigen and an intracellular activation domain
of the TCR (Fig.1.6). These receptors are capable of recognizing intact membrane
proteins irrespective of HLA restriction or antigen processing so that, in contrast to
natural TCRs, CARs do not need to be matched to the patient’s tissue type and a
single CAR can be used to target all patients. Upon binding of their ligand CAR
transduced T cells are then activated in a way very similar to that of the endogenous
TCR. As most tumour-associated targets are self-antigens that are also expressed in
normal tissues, a major advance in adoptive T cell therapy is the ability to efficiently
endow patients T cells with reactivity for tumour antigens through the adoptive
transfer of CAR expressing T cells [59, 60]. In table 1.2 a direct comparison of
TCR engineered versus CAR T cell therapy is explained. The design of CARs and
their structural evolution will be discussed in more detail in section 1.3.3, prompting
the research aims of this PhD project.
T cell receptor genes Chimeric Antigen Receptors
Targets processed intra- & extracellular peptide antigens Restricted to antigens expressed on cell surface
Requires HLA matching HLA independent antigen recognition
Triggers through the signal transduction machinery used
by the native TCR
Signal amplification derived by synthetic biology
Subject to the same counter-regulatory circuits that physi-
ologically downregulate TCR signaling
Possible tonic signaling, leading to unrestrained cellular
activation that results in apoptosis
Low affinity interaction Antibody mediated high affinity interaction
Risk of TCR mispairing No mispairing
Table 1.2: Gene-engineered T cells for cancer therapy
Chimeric antigen receptor (CAR) compared to the T-cell receptor (TCR)
1.3. Adoptive T cell therapy 36
Figure 1.6: Evolution of Chimeric Antigen Receptors.
Schematic representation of 1st, 2nd and 3rd generation CARs
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1.3.1.1 Genetic modification of primary T cells
Effective genetic modification of T cells requires methods that facilitate adequate
gene delivery and adequate expression of functional transgenes [61]. The level
and duration of expression depend on the function required, but in general when
sustained expression is required in highly proliferative T cells, efficient integration
of the vector system and sufficient expression levels are needful.
Viruses are obligate intracellular parasites. Members of the Retroviridae fam-
ily, including γ-retroviruses and lentiviruses, are able to retrotranscribe their RNA
genome into a cDNA copy, which is then stably integrated into the host cell genome.
Following reports of the occurrence of severe adverse events related to the muta-
genic side effects of retroviral insertion in stem cells [62–64], the potential geno-
toxicity of clinical vectors was significantly reduced following the development of
U3-deleted SIN vectors, the use of cellular promoters rather than viral promoter
elements and the switch to lentiviral integration. Lentiviral gene delivery utilizes
viral replication to provide integration of a desired gene, allowing a stable integra-
tion at sites distant from transcriptional start sites which is inherited and expressed
over clonally expanding and persisting T cells. Key for lentiviral vectors is the pro-
duction of self-inactivating particles, allowing for delivery of the desired sequence
whilst reducing the potential recombination with other retroviruses or retrovirus-
like elements that could reconstitute an infectious HIV-like retrovirus[65, 66], T
cell activation or proliferation is not absolutely required for genomic integration.
Lentivectors have been steadily improved over time to increase both their effi-
ciency and biosafety. In the second generation lentivectors, the packaging plasmid
encodes gag-pol, rev and tat, but lacks the rest of viral accessory genes (vif, vpr,
vpu, nef) [65]. Production of infectious virus-like particles carrying the genome of
interest is accomplished by co-transfecting the plasmid encoding the principally de-
fective virus genome (transfer vector) with the plasmids that encode the structural
genes (packaging plasmid) and an envelope glycoprotein (envelope plasmid). Fig-
ure 1.7 shows a schematic representation of the three plasmids forming the second
generation lentivector system. The packaging and the envelope plasmids contain
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a CMV promoter, which controls the expression of HIV-1 proteins. In this figure
the transfer vector contains an expression cassette, made of an internal promoter of
choice controlling the expression of the gene of interest. The packaging signal is
represented as Ψ and the rev response element as RRE.
Both γ-retroviral and lentiviruses have been used in clinical trials of gene-
engineered mature T cells, as shown in table 1.3. To date, no case of insertional
mutagenesis has been reported in either, with a follow up of more than 500 patient
years [67]. CAR gene transfer in this project was achieved using a lentiviral vector,
for its stable integration and safety. However one should take in mind the disadvan-
tages of this method, such as the difficulty of generating of a stable producer cell
line and the resulting costs of this laborious process to produce the vector on a large
scale.
Figure 1.7: Engineering of lentivector system
Adapted from Liechtenstein et al. [65].
There are other (non-) viral methods exploited such as Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated protein 9
(Cas9) system using electroporation or lipid based transfection for genome edit-
ing and efficient sequence-specific interventions. CRISPR-Cas9 technology, orig-
inates from bacteria and provide them with adaptive immunity against viruses and
plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nu-
cleic acids by introducing double-stranded (ds) breaks in target DNA [68]. The
most commonly used type is CRISPR/Cas9 including a conjugation of the tracr-
RNA (trans-activating crRNA)-crRNA complex to a single guide RNA and Cas9.
This same mechanism can be used to introduce site-specific therapeutic genes by
the use of synthetic crRNA/tracrRNA structures, but these still entail a risk of in-
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sertional mutagenesis and they share many of the same safety concerns as retroviral
approaches such as toxicity or immunogenicity of the transgene and delivery modal-
ity [32, 69].
In a recent publication from the Sadelain lab it was shown that targeting a
CD19-specific CAR coding sequence to the TCR α constant (TRAC) locus, plac-
ing it under the control of endogenous regulatory elements by the use of the
CRISPR/Cas9 system, not only results in uniform CAR expression in human pe-
ripheral blood T cells, but also enhances T cell potency, averting tonic signaling and
establishing effective internalization and re-expression of the CAR following re-
peated exposure to antigen [70]. They designed a guide RNA, to disrupt the TRAC
locus and place the CD19-specific 1928z CAR under its transcriptional control.
Approximately 95% of CAR+ cells were TCR-negative, validating the 2-in-1 TCR-
knockout and CAR-knock-in strategy [70]. Another application of CRISPR/Cas9
in CD19 CAR therapy has been described in a study where PD-1 deficient CD19
CAR T cells were generated, to reduce CAR T cell exhaustion as a result of high
levels of PD-L1 expression on tumour cells [71]. PD-1 disruption augmented CAR
T cell mediated killing of tumour cells in vitro and enhanced clearance of PD-L1+
tumour xenografts in vivo. Both these studies demonstrate improved therapeutic ef-
ficacy of Cas9-edited CAR T cells and highlight the potential of precision genome
engineering to enhance next-generation cell therapies.
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1.3.2 CAR T cell therapy for cancer
The first publications of clinical trials using CAR technology were published in
2006 [72, 73], followed by series of successive publications that gave great insights
[74–79]. Successful B cell tumour eradication was obtained with different CD19
CARs [80–82], and multiple early-phase clinical trials with CAR-modified T-cells,
targeting the CD19 molecule, have shown unprecedented responses in the United
States, even in patients with chemorefractory and relapsed disease. The largest stud-
ies of patients with B-ALL treated with CD19-CAR therapy in the United States
and Europe, are summarized in table 1.3 [83–86]. Similar clinical studies are un-
der way in different European countries, with the majority to be conducted in the
United Kingdom. Clinical evaluation of CD19 CAT-CAR is being undertaken in the
CARPALL trial (clinicaltrials.gov, NCT02443831), in which we aim to specifically
study disease response in relation to T cell persistence and T cell fitness.
A number of different groups have attempted to extend the successful findings
in the CD19-field to patients with solid tumours, but the clinical efficacy unfortu-
nately has been modest. One of the targets overexpressed in many different types
of cancer, and therefore prioritised as a potential immunotherapy target, was human
epidermal growth factor receptor 2 (HER2) [91]. Although efficacy was reported
in very preliminary studies [92], in a patient, treated for metastasised colon cancer
with a HER2-targeted CAR, severe dyspnea was observed followed by hypoxia,
pulmonary infiltrates and severe cytokine release syndrome (CRS), and the patient
succumbed most likely due to recognition of low levels of HER2 on lung epithelial
cells, ultimately leading to multi-organ failure [93].
Other targets such as mesothelin, GD2, CD123, MUC16 and others are being
tested both in a pre-clinical as well as a clinical setting, but are outside of the scope
of this thesis.
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1.3.2.1 CD19 as tumour associated antigen
Tumour associated antigens (TAAs) are self-antigens which are expressed on
healthy tissue but are aberrantly expressed on tumours. CD19 is a 95-kDa trans-
membrane glycoprotein of the immunoglobulin superfamily containing two extra-
cellular immunoglobulin-like domains and an extensive cytoplasmic tail [94]. Its
expression is restricted to lymphocytes of the B-cell lineage and is part of the B
cell receptor co-complex. In the bone marrow, CD19 amplifies pre-B cell receptor
signalling, inducing the proliferation and differentiation of late pro-B cells. The
CD19 pathway in healthy and neoplastic B-lineage cells results in the activation of
growth-promoting kinases, via interactions with the CD19 cytoplasmic tail[95].
The density of CD19 on the cell surface is accurately regulated at all stages
of maturation and is gradually lost during terminal differentiation to plasma cells.
CD19 is not expressed on cells of any other lineage, nor is it expressed on non-
haematopoietic cells. The expression of CD19 at normal to high levels, by the vast
majority (>95% ) of non-Hodgkins lymphomas and B-lineage acute lymphoblastic
leukaemia, renders this molecule an attractive target for adoptive T cell therapy,
enabling targeting of malignant cells without toxicity to the non-haematopoietic
tissue [96].
Although it has been described that the extracellular domains are needed for
mature B-cell function, the role of these ectodomains in the proliferation and dif-
ferentiation of normal B-lineage precursors is unknown, and its role in B-cell neo-
plasm is not yet understood [95]. Despite the promising clinical responses of re-
lapsed/refractory (r/r) B-ALL patients to CD19-CAR T cell therapies, a significant
number of patients still relapses. An interim report on the efficacy and safety of
CTL019 in the first US phase II multicenter trial in paediatric r/r ALL stated an
overall response rate (ORR) of 90%, only a relapse free survival after 6 months of
66.4%, indicating that about one third of the patients relapses within a short period
of time after infusion of the CAR T cells [97]. In this context there are two types
of relapses recognized on the basis of their phenotype: 1) CD19+ relapse: these
relapses are typically linked to poor T cell function or persistence; 2) CD19-ve re-
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lapses resulting from selection of antigen negative variants that can evade tumour
surveillance by CD19-CAR T cells. Recent publications have estimated that CD19
epitope loss takes place in 10% to 20% of paediatric B-ALL treated with CD19-
directed immunotherapy [86], leading to discussions regarding its importance in
neoplastic growth. CD19-ve relapses are observed in B-ALL patients treated with
different CAR products, independently of the construct (different costimulation do-
mains) and expansion/clinical protocol [98].
Sotillo et al’s publication described, for the first time, the characteristics of
both CD19 positive and CD19 negative relapsed patient’s samples. They charac-
terized those samples, performing whole-exome sequencing and RNA sequencing.
Firstly, any increase or changes in methylation of CD19 promoter or enhancer el-
ements were ruled out, which could have potentially led to gene silencing. PAX5,
which is the regulator of CD19 transcription was also not downregulated, as shown
by qRT-PCR. Interestingly however, de novo genomic alterations found to primar-
ily affect exon 2, leading to a N-terminal truncated CD19 ∆ex2 isoform were seen.
These genomic alterations consisted of clustering of nonsense and missense muta-
tions, that in contrast to distributed frameshift mutations did not lead to complete
CD19 loss or changes in signalling, required for leukaemic maintenance. This iso-
form was predominantly located in the cytosol. A novel combinatorial mechanism
was identified, by which the CD19 protein was partly conserved by removing the
cognate epitope on the cell surface. It has not been clarified yet, whether these
mutations are de novo mutations, resulting from actively redirecting the splicing
machinery, or whether there is a selective advantage of pre-existing CD19 ∆ex2
isoform clones.
It has also been demonstrated by Jacoby et al., that persistent CD19 CAR pres-
sure can also lead to lineage switching of the malignant clone as a mechanism of
CAR resistance [99]. This lineage switching, determined by the cells inherent lin-
eage plasticity, is a result of reprogramming induced by elimination of the B-cell
transcription factors, resulting in complete loss of B-cell developmental pathways.
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1.3.2.2 Toxicities of CAR T cells in patients with ALL
Although the summarized studies differ in their CAR design, production protocols
and CAR T cell dose, as well as the patient’s baseline characteristics, disease burden
and prior lymphodepleting chemotherapy, all observed strikingly similar toxicities,
relating to cytokine release, neurologic toxicities and off-tumour on-target related
B cell aplasia.
Cytokine Release Syndrome
Cytokine Release Syndrome (CRS) is the most common severe toxicity seen
after CAR T cell treatment, with potentially fatal outcome [100]. It is characterised
by a systemic inflammatory response, that becomes apparent hours to days follow-
ing CAR T cell infusion. There is a marked increase in pro-inflammatory cytokines,
related to T cell activation and expansion (sIL-2Rα, IFN-γ) and activated mono-
cytes/macrophages (IL6, IL10, MIP1β). Clinical features include fevers, myalgias,
malaise and, in more severe cases, a capillary leak syndrome associated with hy-
potension, hypoxia and occasionally renal dysfunction and coagulopathy [7].
Published research suggests that there is a correlation between the occurrence
of CRS and clinical outcome, however no strong correlation was found between the
degree of CRS and outcome [83, 85, 86]. Recent work of Teachey et al., identifying
predictive biomarkers for CRS, conclude that, although there seems to be a correla-
tion between disease burden and CRS severity [83, 86], this alone is not sufficient
to predict CRS severity.
When evaluating standard clinical laboratory tests to predict CRS severity,
none of the following markers were informative, as they all peaked after patients
became ill: ferritin, CRP, LDH, ASAT, ALAT, BUN and Cr. An increase in solu-
ble IL-6-Receptor (Sgp130) and IFN-γ however, was strongly associated with the
development of CRS.
The cornerstone treatment of CRS is IL-6 directed therapy. Tocilizumab, an
IL-6R inhibitor, has shown to be effective in quickly reducing and resolving the
clinical symptoms of CRS, without seemingly affecting the efficacy of the CAR T
cells [83, 85, 86].
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Additional variables not studied by Geyer et al. that may predict severe CRS
include T cell phenotype of the product, T cell function of the product, CD19 poly-
morphisms that may differentially activate CTL019, tumour expression of CD19 or
PD-L1, and immune gene polymorphisms [7].
Neurologic toxicities
A broad spectrum of neurological symptoms has been reported, following
CAR T cell infusion, occurring apparently independent of CRS. The majority were
reversible and self-limiting, and included delirium, encephalopathy, hallucinations,
seizures, confusion, aphasia or word-finding difficulties [83]. In adults with ALL,
a number of deaths from cerebral oedema has recently led to the cessation of Juno
JCART15 programme. The mechanism for neurotoxicity is at present unclear. In-
terestingly, in all patients reported to show neurological symptoms, CARs were
present in their cerebrospinal fluid (CSF). There is no concordance on the diagnos-
tic value of imaging by either CT or MRI, as conflicting results were seen between
the UPenn/CHOP cohort and the NCI trial, but it is considered informative to ex-
clude important differential diagnoses.
B-cell aplasia
B cell aplasia is an expected ”on-target, off-tumour” toxicity and considered
tolerable. Chronic B cell aplasia can lead to hypogammaglobulinaemia which can
effectively be managed by the infusion of replacement therapy gamma-globulins.
As CAR T cells target CD19, a part of the B cell receptor complex, both leukaemic
and healthy B lymphocytes are eradicated. It serves as quite a useful marker for
CAR T cell persistence and functionality.
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1.3.3 Evolution of CARs
The general structure of CARs consists of four elements, the antigen binding do-
main, the hinge or spacer region, the transmembrane domain and the intracellular
domain. CAR design has progressed through different generations, via a largely
empiric process, to improve its signalling output. The first-generation CAR did not
have costimulatory elements incorporated, that later proved to be needed for full T
cell activation. Although these CAR T cells were able to generate a cytotoxic re-
sponse in murine models [101], the clinical outcome of these first generation CARs
were disappointing [74, 90]. The subsequent second and third generation CARs
contained either one or two costimulatory domains[102–104], as illustrated in fig-
ure 1.6. Details and function of the different elements are discussed below.
1.3.3.1 Activation domain
In physiological T cell activation the TCR co-localizes with CD3 - composed of
dimers comprising four subunits ζ, δ, ε, γ - which then initiates the first TCR sig-
nal. In CARs CD3ζ alone proved to be sufficient to induce signals with similar
potency to the normal TCR/CD3 signalling and was chosen as the preferred moi-
ety for CAR signalling [105]. For effective activation however, naive T cells de-
pend upon more than one stimulus. Although the presentation and engagement of
a peptide in the context of HLA is essential for the onset of the activation path-
way through the TCR, without costimulatory signals the ligation of the TCR alone
is insufficient and results in hyporesponsiveness [106]. An early study in which
naive/resting T cells of transgenic were transduced with an scFv and TCR ζ -chain
confirmed this two-signal hypothesis by demonstrating insufficient proliferative and
cytotoxic responses after triggering of the scFvCD3ζ protein [107]. The CD28 sig-
nalling domain was first introduced as a costimulatory moiety. After incorporating
both the primary and costimulatory signalling domain in a single gene product, T
cells transduced with this construct showed enhanced cytokine production [102].
Several following studies demonstrated that the addition of the CD28 costimula-
tory domain improved activation, proliferation and cytokine production by CAR T
cells in vitro and greater tumour cell killing in preclinical animal models using both
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solid tumours and leukaemia that lack the expression of the CD28 receptor ligands
CD80 and CD86 [108–112]. This has been confirmed in an elegant double marking
study in humans which demonstrated T cells transduced with a second generation
CAR incorporating CD28 expanded and persisted better than autologous T cells
transduced with a CAR lacking a costimulatory domain [113].
CD28 co-stimulation is thought to be fundamental for early activation of naive
T cells, but of less significance in memory and effector T cell responses. Additional
co-stimulatory molecules cooperate in different T cell subsets at different stages of
activation. Inducible co-stimulator (ICOS)2, OX40 (CD134) and 4-1BB (CD137)
are expressed upon signalling through CD28 and are thought to be important in ex-
tending the T cell response and the origination of T cell memory [114]. ICOS is a
B7 receptor family member, OX-40 and 4-1BB are TNF receptor family members
and all are expressed on activated T cells. Subsequent to the incorporation of CD28
as a co-stimulatory domain in a CAR, 4-1BB as a co-stimulatory domain was tested
in a CAR format. Signalling via 4-1BB was selected because it has been shown
to induce expansion of CD8+ cells, and enhancement of CD8+ T cells responses
[115, 116], but more notably it causes up-regulation of anti-apoptotic genes which
is thought to protect the transduced cells of activation induced cell death (AICD)
[117]. Persistence of transduced T cells has been a considerable impediment to the
use of these cells for adoptive immunotherapy, as poor in vivo persistence has been
reported to result in reduced potential clinical activity [73, 74], and improving this
is therefore a cornerstone of ongoing investigations. Milone et al. showed that the
CARs containing the 4-1BB co-stimulatory domain have superior antileukaemic
efficacy and improved persistence in a primary human ALL xenograft model [81].
This was supported by another study again showing greater persistence but this time
with a mesothelin targeting CAR [118]. CARs containing the 4-1BB co-stimulatory
domain have also been associated with clinical success targeting CD19 [76, 89] and
a recent publication by Long et al. provides a biological explanations for the in-
creased persistence of 4-1BB incorporating constructs compared to those incorpo-
rating a CD28 co-stimulatory domain [119]. They show that the amelioration of ex-
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haustion correlates to a unique transcriptional profile. Several key genes described
to contribute to exhaustion were differentially expressed between cells transduced
with a CD28 co-stimulatory domain containing construct compared to 4-1BB. Their
results suggest that quantitative reductions in exhaustion-associated molecules may
contribute to the improved persistence. In third-generation CARs, multiple co-
stimulatory domains are placed in tandem, however limited data is published of the
clinical experience using these constructs [120]. Pre-clinical in vitro studies exhib-
ited superior proliferation, interferon-γ secretion and cytotoxicity [121], compared
to second generation CARs transduced with a CD28 co-stimulatory domain.
In view of the complex cellular, signalling, and metabolic status in tumour le-
sions, there is considerable interest in understanding the impact of CAR-mediated
costimulation on T cell performance. An interesting study on specific metabolic
pathways by Kawalekar et al. addresses the impact of costimulation on metabolic
plasticity of human engineered CAR+T cells, through different signalling path-
ways and towards different maturation stages. Inclusion of 4-1BB as co-stimulatory
molecule promoted the outgrowth of CD8+ central memory T cells that had signif-
icantly enhanced respiratory capacity, increased fatty acid oxidation and enhanced
mitochondrial biogenesis. In contrast, CAR T cells with CD28 domains yielded
effector memory cells with a genetic signature consistent with enhanced glycoly-
sis [122, 123]. The study on the impact of CAR costimulation on the metabolic
reprogramming of CAR T cells advances the understanding how to manage T cell
metabolism and to balance the redirected response toward long-lived memory cells
[123]. The constructs used in all the experiments conducted for this thesis incor-
porated a 4-1BB costimulatory domain, with the anticipation of accomplishing en-
hanced T cell persistence.
1.3.3.2 Spacer and transmembrane domain
It can be difficult to mimic the structural and spatial elements of T cell recognition
that has evolved to very closely regulate the interaction between the T cell and
its target. During formation of the immunological synapse, the 15-nm distance
between a T cell and an APC is dictated by the structures of the TCR and pMHC
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[124]. This close proximity is important to exclude the phosphatases CD45 and
CD148, which have large ectodomains, from the synapse to allow TCR-induced
tyrosine phosphorylation to be initiated in the absence of these negative regulators
[124]. Unlike a T cell receptor contact with peptide-loaded HLA class I or II, CARs
adapt to a different dimensional connection and the synapse between a CAR and
target cell is influenced by the scFv’s epitope location and the spacer region, relative
to the distance from the tumour cell’s plasma membrane. CARs do not form a
traditional synapse, showing differences in Lck and actin distribution. The LFA-1
integrin is known to mediate adhesion between T cells and antigen-presenting cells
and CAR T cells exhibit reduced accumulation of LFA-1 in the synapse, which may
contribute to reduced adhesion and facilitate detachment from tumour cells [125].
Moritz et al. designed a CAR that, in contrast to earlier reported versions that
attached the scFv directly to the CD3ζ domain [126], added a flexible hinge mo-
tif derived from the membrane proximal portion of CD8 and laid the foundation
for several transmembrane domains tested. The connecting sequence between the
antigen recognition domain and the transmembrane domain directly influences the
orthogonal synapse distance and flexibility between CAR T cell and target cell. Ex-
amples of spacer regions include immunoglobulin domains such as the Fc region of
IgG or the immunoglobulin-like extracellular regions of CD4 and CD8. There are
somewhat conflicting results as to what would be the optimal design of the spacer
or hinge region. Guest et al. compared CARs targeting carcinoembryonic antigen
(CEA), neural small adhesion molecule (NCAM), 5T4 and CD19, investigating the
influence of adding an IgG derived hinge region on CAR T cell functionality. While
5T4- and CD19-specific CAR-T cells with a hinge had enhanced effector function,
CEA- and NCAM-specific CAR-T cells had optimal activity without [127]. Sim-
ilarly, Hudecek et al. compared the effect of different lengths of hinge regions on
ROR1 CAR T cells, showing an improved functional outcome in ROR CAR T cells
containing a short hinge region [128]. Targeting CD30 however, a different research
group had found that the inclusion of an Fc hinge region reduced cellular activity
upon encounter of antigen, compared to CAR T cells without any spacer domain
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[129]. Thus where in some cases no spacer or very short hinge regions seemed
to result in an optimal functionality of the CAR transduced cells, others have re-
ported that a more flexible spacer may be required to permit the efficient binding
of epitopes residing closer to the cell membrane [127–131]. These results clearly
illustrate that the choice for a spacer region is target dependent and that modify-
ing this region is likely to significantly impact the receptor stability and substrate
binding affinity, depending on the location of the target epitope. In addition, detri-
mental effects of the hinge region have also been described. Cross-activation can
occur between IgG1 Fc-hinge-containing CAR T cells and Fcγ-receptor-positive
cells, resulting in unspecific innate immune activation and AICD [132, 133].
When comparing the effect of the spacer region in the CD19 trials, potent
antitumour activity has been shown against chronic lymphocytic leukaemia, using a
short spacer region derived from the human CD8α-chain [76, 77]. Limited reports of
persistence and clinical efficacy have been published with a longer spacer domain,
derived from the IgG1 hinge and fc [113], thought to be caused by the endogenous
immune response against the murine component [90]. In the context of this thesis
the hinge and transmembrane region of the human CD8α-chain were cloned in-
frame between the scFv and the signalling domains, identical to the CAR construct
taken forward for clinical evaluation in the CARPALL trial.
1.3.3.3 Antigen binding domain
An immunoglobulin is a 4 chain-structure consisting of two identical heavy and
light chains (V H & V L), as shown in figure 1.5. Antigen recognition is mediated
by a combining site in the variable fragments (Fab) that requires contributions from
both the V H and V L. Within these two domains are three hypervariable regions
termed complementarity determining regions (CDRs) between flanking framework
regions, which are more highly conserved. CDRs can interact and determine bind-
ing to the antigen.
As indicated earlier, the binding domain most commonly incorporated into a
CAR is an scFv, consisting of the immunoglobulin light chain variable region (VL)
and the heavy chain variable region (VH) linked by a peptide linker sequence, retain-
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ing its specificity and affinity and enabling MHC-independent antigen recognition
[134]. Individual scFvs targeting a surface molecule are either derived from murine
or humanized antibodies or synthesized and screened via phage display libraries. A
major challenge in CAR design is ensuring specificity to the tumour, whilst sparing
healthy cells.
A wide array of antigens has been exploited to target with a CAR. There are 6
hybridomas producing murine monoclonal anti-human CD19 specific scFvs avail-
able [96, 135–139]:
• SJ25C1, Mouse IgG1
• FMC63, Mouse IgG2a
• 4G7, Mouse IgG1
• HD37, Mouse IgG1
• CAT-13.1E10, Mouse IgG1
• B43, Mouse IgG1
Of these, 4 have been used in clinical CD19 CAR studies to date. Studies per-
formed by the NIH and University of Pennsylvania have used an scFv, derived from
the FMC63 hybridoma, whereas studies at the Memorial Sloan Kettering Cancer
Center used an scFv derived from the SJ25C1 hybridoma [79, 89, 140]. Studies
performed at UCL have used FMC63, 4G7 and CAT. The amino acid sequence
alignments of the variable domains (V H & V L) are shown in table 1.4. The
use of murine scFv sequences can induce immunogeneicity resulting in a poten-
tial advanced reactivity against and early evanescence of the CAR-transduced cells
[73, 74]. Humanizing the foreign sequences of the scFv or using a fully human scFv
can render them less immunogenic. However one could still develop anti-idiotype
antibodies that may be inhibitory.
1.3.3.4 Impact of CAR T cell receptor affinity on T cell function
The upper limit of natural TCR affinity correlates to a dissociation constant (KD)
of around 1 - 50 µM [142, 143]. This is considerably weaker than reported affini-
ties for protein-protein interaction and the antibodies used for CARs. Although
higher affinity interactions increase specificity for a ligand, a quick dissociation
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rate has been described to be of particular importance, as T cell functional avidity
can be detrimentally affected when dissociation is prolonged [31]. As described
earlier, in contrast to the natural TCR, CARs employ a different mechanism by
which they recognize antigens in an MHC-independent manner. CARs, through
their binding domains, recognize membrane-bound cell surface antigen, typically
with a higher affinity (KD= 80-1 nM) compared to TCR-pMHC affinity. However,
because CAR transduced cells bind to antigens independent of MHC, the increased
avidity through co-receptor engagement might be less distinct compared to wild
type TCR and the difference in overall avidity between wild type TCR and CAR is
therefore unidentified and possibly not as considerable as formerly thought.
Avidity of CAR-transduced cells is co-determined by the density of CAR on
the cell surface and the antigen expression density. Whether differences in the
affinities of the CD19 targeting domain, when significantly different, could affect
CAR-mediated T cell functionality has not been evaluated, while previous studies,
investigating different targets and CARs have to some extent been contradicting. A
functional and dynamic balance between CAR expression density and TAA density
has been described, showing that high levels of CAR expression lead to T cells be-
ing triggered by both low and high expressed TAAs, whereas low levels of CAR
expression lead to CAR T cells being unable to lyse and produce cytokines in re-
sponse to low expressed TAAs. There appears to be a window within which the
level of CAR expression does not seem to impact T cell activation [144], however
exceeding this level of expression, transduced cells are susceptible to AICD fol-
lowing engagement to its target [145]. The threshold for complete T cell activation
is readily met, regardless of CAR affinity, due to high numbers of simultaneous
CAR-antigen binding events [146].
Different studies showed there is a functional threshold affinity beyond which
no improvement in T cell function is achieved, defined as ”the affinity ceiling”.
Chmielewski et al. described a threshold of 1.6x10−8M and Haso et al. compared
2 CARs with binding domain affinities of 5.8x10−9M and 2.3x10−9M showing no
significant differences between the two [147, 148]. Transduced cells, binding with a
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strength above this window, are susceptible to activation induced cell death (AICD)
following engagement to its target [149], as well as non-specific target recognition
[150]. When the expression levels of CAR and/or antigen are low however, the
optimal affinity remains elusive [146, 147, 151, 152]. Variances in outcome could
be attributed to stability of the binding domain and mechanisms by which affinity
of binding domains were altered, affecting either on- or off-rate.
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1.4 Aims & Objectives
The overarching aim of this project is to investigate the impact of scFv affinity, and
in particular the off rate, on CAR-mediated T-cell function both in vitro and in vivo.
Specifically, my objectives are:
• To generate 6 CARs that are identical in backbone other than their CD19-
targeting domain, incorporating the 6 different CD19 binding scFvs;
• To compare the affinity of the 6 scFvs;
• To phenotypically characterize T cells transduced with the different affinity
CD19 CARs;
• To characterise the effect of affinity on CAR+ T cells by investigating func-
tional responses in vitro, studying proliferation, differentiation, target cell
killing, and the production and secretion of effector cytokines;
• To perform live cell imaging, to investigate the impact of differences in CAR
affinity on interactions between CAR T cells and their targets on a micro-
scopic level; and
• To study the anti-tumour response of different affinity CARs in a clinically
relevant xenograft NSG model of disseminated leukaemia.
Chapter 3 details the experiments, investigating the affinity of the different anti-
CD19 binding domains. Chapter 4 sets out the phenotypic characterisations and
CAR+ T cell functional responses, using various in vitro techniques. Lastly, the
anti-tumour response in several subsequent in vivo studies, using a xenograft NSG
model of disseminated leukaemia, are being discussed in chapter 5.
Chapter 2
Materials and methods
2.1 Materials
2.1.1 Blood samples, cell lines, buffers, media and solutions
Cell line Description Distributor
Raji Burkitt Lymphoma cell line ATCC
NALM6 B cell precursor leukaemia, ffLuc-eGFP-expressing Gift from Hilde Almasbak
SupT1 T cell lymphoblastic lymphoma cell line ATCC
SupT1 CD19 T cell lymphoblastic lymphoma cell line transduced to express
CD19
Gift from Martin Pule
MP23021 SupT1 CD19 T cell lymphoblastic lymphoma cell line transduced to express
CD19 at a low level (CD19 expression = 150x lower than
supT1 CD19)
Gift from Martin Pule
K562 CD19 Chronic myeloid leukaemia cell line transfected to express hu-
man CD19-rabbit IgG1 recombinant protein
Gift from Martin Pule
HEK293 T cells Human embryonic kidney cell line ATCC
Table 2.1: Cell lines
Peripheral blood was taken from healthy volunteers after their informed consent.
All cell lines used in this report were validated by PCR to be free from Mycoplasma
(MycoAlert Mycoplasma Detection Kit, Lonza). Raji, K562 and 293T cell lines
were obtained from ATCC. SupT1 cells were purchased from ECACC and trans-
duced with an SFG vector to express human CD19 (SupT1-CD19) and single cell
selected by flow cytometry to generate a cell line, this work was done my members
of Martin Pule’s lab. K562 cells were transduced to express human CD19-rabbit
IgG1 recombinant protein. NALM6 cells expressing GFP and firefly luciferase were
kindly provided by Dr.Hilde Almasbak. Unless otherwise stated, all culture medium
was Roswell Park Memorial Institute (RPMI)1640 plus 10% heat inactivated fetal
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calf serum (FCS) (R10). K562 and 293T cells were cultured in Dulbeccos Mod-
ified Eagle Medium (DMEM) supplemented with 10% FCS (D10). All cell lines
were kept in 5% CO2 humidified incubators at 37◦C. Adherent cell lines were rou-
tinely cultured to 70-80% confluency, then passaged 1:10 following dissociation
with 0.05% Trypsin-EDTA (Gibco).
Stock solutions:
10mM PEI - Adjust 50ml PBS to pH4.5 using HCl. Weigh 10.3g polyethylen-
imine (Sigma-Aldrich 40872-7) into a 50ml falcon tube, add 31ml PBS pH4.5, place
in a 75C water bath and vortex every 10 min until completely dissolved. Aliquot
and store at -80C.
2.2 Methods
2.2.1 Molecular biology techniques
2.2.1.1 Generation of plasmids
Lentiviral vector
Figure 2.1: Schematic representation of the self-inactivating lentiviral transfer vec-
tor used in this thesis.
CMV Heterologous CMV transcriptional promotor
LTR Long terminal repeat: controls gene expression
R R region: start of transcription
U5 5′ untranscribed region, involved in reverese transcription
Ψ Packaging signal: required for encapsidation of viral genome
RRE Rev response element
cPPT Central polypurine tract: provides increased transduction
PGK Human phosphoglycerate kinase promotor
ΔWPRE Mutated woodchuck hepatitis virus post-transcriptional response element: improves nu-
clear export of mRNA
ΔU3 3′ untranscribed region, functional HIV-1 promotor and contains transcriptional en-
hancers, which have been mutated so the vector is self inactivating
The pCCL-aCD19 scFv-41BBZ lentiviral vector encodes the pCCL lentivi-
ral backbone, in which the enhancer and promoter of CMV are joined to the R
region of HIV-1 and the aCD19 scFv-41BBZ CAR. A schematic representation
of the vector is given in figure 2.1. The CAR consist of an anti-CD19 scFv de-
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rived from available mouse hybridomas, a portion of the human CD8 stalk and
41BB molecule, and the intracellular component of the human TCR-ζ molecule.
The compact marker/suicide gene RQR8 was coexpressed with CAR by cloning it
upstream of the CAR separated by an in-frame 2A ribosomal skipping sequence.
[153]. RQR8 was later replaced by genes encoding for the marker gene mCherry.
To encode the anti-CD19 scFv components, previously published DNA se-
quences were used [96, 135–139]. The generated sequence encoded the following
components: a NcoI site, a signal peptide, the variable heavy chain, a serine/glycine
linker, the light chain and a BamHI site. All constructs were generated by gene syn-
thesis using polymerase chain reaction (PCR) assembly of overlapping oligos, see
chapter 2.2.1.2.
Soluble single chain fv-Fc
For affinity measurements the different aCD19 scFvs were fused to
mouse IgG2a-Fc and generated in a secreted format. MP13227(SFG.dCD19-
mIgG2aFc.I2.eBFP2) was used as the parental construct and cut with NcoI and
BamHI after which the correspondingly digested scFvs were ligated into this plas-
mid.
Cloning of truncated CD19 isoforms
We constructed the full length peptide and three variants with increasing trun-
cation of CD19 (∆2, ∆2− 3, ∆2− 3− 4) as displayed in figure 3.4, including a
V5 tag (template from MP14479) under the signal-peptide. The cDNA fragments
for CD19 (template dCD19-MluI MP14012) and the truncated isoforms were or-
dered as GBlocks (IDTDNA) with NcoI/MIuI restriction sites and the constructs
were cloned into the retroviral vector SFG.I2.eGFP (MP3279) with NcoI/MluI re-
striction enzymes, followed by ligation. For completeness we included a full length
(ecto) CD19 in the same format.
2.2.1.2 Oligo assembly
Oligonucleotides were purchased from IDTDNA. By PCR assembly of overlapping
oligos, short stretches of DNA are synthesized. To amplify the full length product,
forward and reverse primers were used. The oligos were reconstituted at 100µM.
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10µl of each oligo was pooled in an eppendorf. To perform the assembly PCR,
three dilutions of the oligo pool were prepared at 25 µM, 12.5 µM and 6.25 µM.
With each of these dilutions as a template the PCR was then set up using: 36.5µL
Nuclease-free water, 10µL Phusion HiFid buffer (NewEngland Biolabs), 2µL of
pool template, 1µL of Deoxynucleotide (dNTP) Solution Mix (NewEngland Bio-
labs) and 0.5µL of Phusion hot-start polymerase (NewEngland Biolabs). The PCR
thermocycles were as follows: 98◦C for 2 minutes, 98◦C for 1 minute,65◦C for 45
seconds, 72◦C for 1 minute, repeat cycle 2 35x, 72◦C for 10 minutes and then 4◦C
until sample is retrieved.
To perform the amplification PCR, the PCR product was purified using the Qi-
agen PCR clean up kit and eluted in nuclease free water. The PCR was then set
up as follows: 35.5µL Nuclease-free water, 10µL Phusion HiFid buffer (NewEng-
land Biolabs), 2µL of cleaned-up template, 1µL of forward primer, 1µL of reverse
primer, 1µL of dNTP Mix (NewEngland Biolabs) and 0.5µL of Phusion hot-start
polymerase (NewEngland Biolabs). The PCR thermocycles are described above.
The product was then purified again and, after determining its size using agarose
gel electropheresis, digested with restriction endonucleases.
2.2.1.3 Agarose gel electropheresis
Agarose gel electrophoresis was used for separation of DNA fragments by size. Mi-
gration rates are dependent on the pore size of the gel, which is determined by the
agarose concentration. Optimal resolution of the fragments of interest was achieved
by using 1% agarose, which ensures 0.25 - 12kb range of separation. Excised bands
were purified using a gel extraction kit (QIAGEN) following manufacturers proto-
col.
2.2.1.4 Triple ligation
The construct pCCL.PGK.RQR8-2A-aCD19-4g7-HL-CD8STK-41BBZ (MP20151)
was produced prior to the commencement of this PhD and was used as the parental
construct. NcoI is not a unique cutter for this construct and since the newly gen-
erated scFvs have NcoI/BamHI restriction sites, a triple ligation strategy was set
up. Two different digestions with MP20151 were set up as seen in table 2.2. CAR
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insert and lentiviral backbone were identified as DNA fragments by agarose gel
electrophoresis and stained with ethidium bromide for visualization under ultravi-
olet light exposure. Bands were excised and purified (Qiaquick Gel Extraction kit,
Qiagen), and then ligated at a molar ratio of MP20151 I 1: MP20151 II 4.5: scFv
4.5.
MP20151 I MP20151 II scFv
NEB3.1 (µl) 10 10 10
H2O (µl) 75 75 75
Enzyme I (5µl) SalI SalI BamHI
Enzyme II (5µl) BamHI NcoI NcoI
DNA (µg) 5 5 5
Fragmentsize (bp) 7771bp 541bp approx. 800bp
Table 2.2: Triple ligation for CD19 CAR
2.2.1.5 Restriction enzyme digestion
DNA digestion and restriction patterns were used to accurately verify successful
cloning and presence of inserts. The mixture for digestion is set up as follows: 1 µg
DNA, 2 µL NEB Buffer, 0.5 µL Enzyme 1, 0.5 µL Enzyme 2, 1 µL 1 in 10 diluted
BSA, filled up to a total volume of 20 µL with nuclease free water. This mixture
was then incubated for a minimum of 1 hour at 37◦C.
2.2.1.6 Transformation of plasmid DNA from E.Coli
Heat shock transformation of NEB5α competent bacteria (C2987H, high efficiency,
New England Biolabs) allows the introduction of a circular DNA plasmid which
confers resistance to a particular antibiotic granting later selection with that antibi-
otic. It was done by, after thawing, carefully adding 1 µl plasmid and incubating
the bacteria on ice for 30 minutes, after which bacteria were incubated at 42◦C for
35 seconds and subsequently incubated on ice for 5 minutes. Following addition
of 250µL SOC media, samples were shaken at 200 rpm for at least 40 minutes at
37◦C. Transformed bacteria were then spread onto antibiotic-containing agar plates
(the antibiotic used for selection was dependent upon the plasmid being amplified)
cultured at 37◦C for 12-16 hours and bacteria clones positive for the backbone were
then identified.
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2.2.1.7 Mini/Midi-prep of plasmid DNA
Twelve clones were selected for mini-culture in LB media with antibiotic selection
at 37◦C for 16 hours. Preparation of DNA from minipreps was done via MiniPrep
kit (Qiagen) and subsequent analytical digestion with restriction enzymes and anal-
ysis of fragment size by agarose gel electrophoresis identified clones positive for the
construct. Positive clones were then checked by sequencing to confirm successful
cloning. A correct clone was then inoculated into large culture in TB media with
antibiotic selection and cultured on shaker at 37◦C for 16 hours, until log-phase
growth was achieved. DNA was isolated from bacteria using EndoFree Midi Prep
kit (Qiagen). Spectrophotometer analysis of DNA verified purity by OD260/280
reading between 1.8 and 2.0.
2.2.1.8 Quantification of DNA
The absorbance of the final midiprep solution was measured on a spectrophotometer
set to record at 260/280 nm wavelength. To determine the purity of DNA a ratio of
A260/280 > 1.8 was pursued.
2.2.1.9 Sequencing
All the new constructs were sent for sequencing to confirm successful cloning
(Beckman Coulter). The results were analysed and sequence alignment was per-
formed using Snapgene software.
2.2.2 Cell culture techniques
2.2.2.1 Lentiviral vector production
Vectors were produced by transient transfection into 293T cells. 293 T cells were
chosen as the packaging cell line for the production of the lentiviral particles due
to its ease of transfection. The day before transfection 20-25 x 106 293T cells were
in 20ml D10 per 15cm dish - they should be 85-95% confluent on the day of trans-
fection - the growth rate of 293Ts can be variable so this cell number may need
adjustment. A full prep required 20 plates. On the day of transfection, for each dish
of 293Ts 5ml of Optimem containing 50 µg vector plasmid, 17.5 µg pMD2.G plas-
mid (VSV-G envelope), and 32.5 µg pCMV-dR8.74 (Gag/pol packaging) plasmid
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was prepared and sterilised using a 0.22 µm filter. In separate flasks 1µl 10mM PEI
to 5ml Optimem was added for each dish and filtered. The DNA and PEI solutions
were combined in a 1:1 volume ratio (mixing continuously) and incubated at room
temperature for 20min to form transfection complex solution. 10ml of transfection
complex was added dropwise into the complete DMEM in each flask containing
293Ts and incubate at 37C 5% CO2 for 4h, after which the the PEI:DNA complex
was removed and replaced with D10. The following morning media was replaced
with 12mls of fresh media per plate and 48 hours after transfection the virus con-
taining supernatant was harvested and concentrated by ultracentrifugation. This
step was then repeated at 72 hours.
2.2.2.2 Vector titration
Vector titre was assessed using 293T cells, seeded at 1x105 cells per well in 1ml D10
per well in a 12-well plate. Cells were incubated in 5% CO2 humidified incubators
at 37◦C for 6 hours.Following incubation, polybrene (MILLIPORE UK LTD) was
added to each well of 293T cells at a concentration of 5µg/ml. Vector sample was
thawed on ice and serially diluted in D10. From the resultant dilutions; 100 µl of the
serially diluted vector was added gently dropwise to each well of 293T cells. Cells
were incubated in 5% CO2 humidified incubators at 37◦C between 60-72 hours.
Following incubation, the vector transduced 293T cells and negative controls were
gently harvested off the 12-well plates using Cell Dissociation Solution (Sigma-
Aldrich) and washed in phosphate-buffered saline (PBS; Sigma-Aldrich). Percent-
age transduction efficiency was assessed by expression for mCherry and titre was
standardised against an in-house lentiviral vector control of known titre. Vector titre
can be estimated across a range of vector volumes (2- 0.00064ul), but the estimate
of stable transducing units was considered most accurate when between 5-20% of
293T cells were transduced.
2.2.2.3 Expression soluble scFv-fc
For expression of soluble scFv-fc 293T cells were transfected, by using Genejuice
transfection reagent (EMD Millipore). In short 293T cells were plated 24 hours
prior to transfection. Number of cells seeded was dependent on growth rate of cell
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line. Generally 1.5x106 cells per entire plate were seeded (either 6,12 or 24 well
plate). When 60% confluency was achieved, transfection was performed. See table
2.3 for amount of media, genejuice and DNA per well. First genejuice and plain
medium were mixed and incubated for 5 minutes. The DNA was then added and
incubated at room temperature for 15 minutes to allow formation of liposomes. The
mix was then carefully added to each well and gently agitated to allow appropriate
mixing.
Well type Genejuice Plain medium DNA
100mm plate 30 µl 470µl 12.5 µg
6-well plate 5 µl 95 µl 2 µg
12-well plate 2.5 µl 47.5µl 1µg
24-well plate 1.25µl 23.75µl 0.5µg
Table 2.3: Genejuice mix
2.2.2.4 Expression CD19 truncated isoforms
The truncated CD19 isoforms were expressed on 293T cells by transient transfec-
tion using PEI, described in section 2.2.2.1. In short 293T cells were plated 24
hours prior to transfection. Number of cells seeded was dependent on growth rate
of cell line. Generally 20x106 cells per 15cm plate were seeded in 10ml D10 . For
transfection 5ml of plain Optimem was needed per plate to which 1µl of 10mM
PEI was added. Another 5ml of plain Optimem was prepared per plate to which
30 µg of plasmid DNA was added. The two were then mixed and incubated for 20
minutes at room temperature. Without removing the cell-culture medium, the 10ml
transfection mix was then added dropwise to each plate.
2.2.2.5 Human peripheral blood mononuclear cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient
centrifugation using FicollPaque Plus (GE Health,UK) at 750g for 25 minutes.
Mononuclear cells were aspirated using a Pasteur pipette into phosphate buffered
saline (PBS) and centrifuged at 220g for 10 minutes. Cells were counted and again
centrifuged at 300g for 5 minutes. The PBMCs were then re-suspended in R10 at a
density of 1 x106 cells/ml.
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2.2.2.6 Activation of human T-cells
PBMCs were initially activated with Dynabeads® Human T-Expander CD3/CD28
(Life technologies) at 1:1 ratio. bead:cell ratio, exogenous Interleukin-2 (Proleukin
®, Novartis) at 100 IU/ml was supplemented to the media throughout the activa-
tion/transduction and expansion phases. Following further optimisation by Dr. Sara
Ghorashian, it was decided to change this protocol to an activation with Dynabeads
at 3:1 ratio, without further addition of cytokines. This proved to result in better
transduction efficiencies whilst retaining an early memory phenotype.
2.2.2.7 Lentiviral transduction of human T-cells
Twenty-four hours after activation, T cells were transduced in a 24 well plate. Acti-
vated T cells were counted using trypan blue exclusion and 1ml of viable cells at a
concentration of 1 x 106/ml in R10 was added to each well. Cells were transduced
at varying multiplicities of infection (MOI, the average number of virus particles
infecting each cell) and were subsequently incubated for 24 hours, after which the
cells were topped up with an additional 1ml of R10, to a total volume of 2ml/well.
The cells were recovered, counted and resuspended at 1 x 106/ml in fresh R10 72
hours following transduction. Anti-CD3/ CD28 beads were removed by magnetic
separation on day 5 post-transduction, after which the transduction efficiency was
determined by expression of mCherry and binding to a recombinant CD19 tagged
with a rabbit IgG1 fc domain. CAR expression was then read out by staining with
a secondary anti-rabbit fc antibody.
2.2.2.8 CD56 depletion
To preclude non-specific target cell killing, proliferation or cytokine production by
natural killer cells (NK cells) in the PBMC preparation used for transduction due
to MHC-I mismatch, cultures were depleted for CD56 expressing cells using CD56
MicroBeads (Miltenyi Biotec), according to manufacturer’s protocol. CD56 is ex-
pressed by essentially all human NK cells and is increased on the cell membrane
after activation. Depletion was performed one day prior to set up of further in-vitro
functional testing, corresponding to 6 days post-transduction.
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2.2.2.9 Culture methods for larger scale production of CAR T cells
Larger numbers of cells were cultured and transduced in G-rex culture vessels
(Wilson-Wolf), a gas permeable rapid expansion culture technology. G-Rex10 gas
permeable surface area = 10 cm2 and therefore 10x106 cells were activated on day
0 in 10ml of R10. Activation protocol was identical to the protocol in plates, i.e.
3:1 bead: cell ratio, without addition of cytokines. The next day (24 hours after
activation) cells were transduced with MOI of 1, based on day 0 count. Twenty-
four hours after transduction, the medium was topped up to a total volume of 40ml
R10. If necessary, medium can be refreshed by carefully replacing 20ml of medium
with 20 ml of fresh R10. Beads were removed 6 days following transduction, after
which the cells were transferred to a MACS GMP Cell Differentiation Bag - 100
(Miltenyi) at 1x106 /ml R10. We validated to ensure the distribution of memory
subsets following culture in Grex was idential to that obtained in plates.
2.2.3 Affinity determination
2.2.3.1 Biacore
Experiments were performed on a Biacore T200 instrument using 0.01 M HEPES
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20 (HBS-EP) as run-
ning and dilution buffer (GE Healthcare Bio-Sciences). Prior to experimental setup
recombinant CD19 protein (sino biologicals or Acro biosystems) was reconstituted
according to the manufacturers instructions and dialysed against HBS-EP at 4◦C
to reduce observed bulk refractive index changes. For binding kinetics, goat anti-
mouse IgG (GE Healthcare) was covalently coupled to a CM5 Sensor Chip (GE
Healthcare). Anti CD19 scFv-Fc (mIgG2a) constructs were then captured at a tar-
get density of 100 response units (RU) and various concentrations of CD19 protein
injected over the flow cell at a flow rate of 30 µl/min. Bulk refractive index dif-
ferences were subtracted using a blank control flow cell in which capture antibody
had been immobilized to the same level as the active surface. A double reference
subtraction was performed using buffer alone in place of CD19 protein, to account
for system baseline drift. BIAevaluation software Version 2.0 (GE Healthcare) was
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used for data processing. Kinetic rate constants were obtained by curve fitting ac-
cording to a 1:1 Langmuir binding model.
2.2.3.2 Cellular affinity by flow cytometry
After production of the soluble scFv-fc an ELISA was performed to quantify the
amount of protein in the supernatant. A 96 well plate (Maxisorp) was coated with
100 µl per well of 1 µg/ml anti-mouse IgG2a in PBS. A second plate was coated
with 100 µl PBS alone. The plates were then incubated for 1hr at room tempera-
ture or at 4◦C over night. After decanting the plates they were blocked with 200
µl of 3% BSA/PBST (PBS containing 0.1% Tween 20) per well for 1 hour at room
temperature and washed twice afterwards. 100 µl of the scFv-fc supernatant or
standards (e.g. purified mouse IgG2a scFv-Fc) were then added at several dilu-
tions to each plate and incubated at room temperature for 1 hr, after which the
plates were washed 3 times with PBST and once with PBS. A hundred µl of 1/4000
anti-mouse IgG-HRP (GE Healthcare) diluted in 1% BSA/ PBST was then added
and incubated for 1 hour at room temperature, after which the plates were again
washed 3 times with PBST and once with PBS. A 100 µl of OPD substrate (one
OPD (o-Phenylenediamine dihydrochloride) tablet (Sigma) was dissolved in 25ml
of phosphate-citrate buffer with sodium perborate immediately prior to use) was
then added to each well and incubated for 5 minutes, after which the reaction was
stopped by the addition of 50µl of 4M HCl. The adsorbance at 490 nm was then
read on a plate reader.
To determine optimal number of Raji cells we performed the experiment in a
serial 1:2 dilution starting at 1x106 Raji cells/well. The cells were pelleted the su-
pernatant was discarded. A 100 µL of scFv-fc (5x serially diluted 1:2 in DMEM
+ 10%FCS) was then to each corresponding well. The samples were incubated at
room temperature for 1 h and placed on ice for 5 minutes afterwards.The decrease
in temperature greatly decreases the off-rate. The cells were then again pelleted and
carefully remove supernatant for ELISA assay (in case needed) The samples were
washed with 200 µL of ice-cold PBS, and resuspended in 100 µL of a 1:100 dilution
of secondary aMuIgG FITC antibody. Cells were incubated on ice for 30 minutes
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after which they were washed and finally resuspended in a 100 µl of cold fixation
buffer before they were analysed by flow cytometry. In the Raji morphology gate
5,000 events were recorded and the statistical information from the FITC MFI was
collected. Autofluorescence of non-stained Raji cells was subtracted before the MFI
against the concentration of cells was plotted. A Scatchard analysis, a method of
linearizing data from a saturation binding experiment in order to determine binding
constants, was performed to fit the curve and determine Kd (Graphpad Prism v7.02).
The first step was to perform a Non-linear Regression (Curve Fit) analysis, specif-
ically the One site binding (hyperbola) assay. The data can then be transformed
to a Scatchard line. Select Analyze and Data manipulations, then Transforms. In
the next dialog, Parameters: Transforms, choose Pharmacology and biochemistry
transforms from the Function List drop-down box, then set the Scatchard radio but-
ton.
The following equation was used: y = m1+m2 ∗m0/(m3+m0) where m1 =
MFI of no antigen control, m2 = MFI at saturation, and m3 = KD. The slope of the
straight line equals −1/KD from which KD can be calculated.
2.2.4 Western Blot
Twenty micrograms of each cell lysate was loaded and separated by 4-20% SD-
Spolyacrylamide gradient gel electrophoresis and then transferred to 0.45-µm
polyvinylidene fluoride membranes (200 V, 50 min). After blocking for 1 h in
Phosphate buffered saline with tween 20 (PBST) (10 mM sodium phosphate, 0.9%
NaCl, and 0.1% Tween 20) containing 5% skimmed dry milk, blots were incubated
either for 1 hour at room temperature overnight at 4◦C with the primary antibod-
ies in PBST containing 5% skimmmed milk. The blots were washed three times
with PBST (40 min) and incubated for 1 h with horseradish peroxidase-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBST
containing 5% skimmed dry milk. Immunoreactivity of the protein bands were de-
tected by enhanced chemiluminescent autoradiography (ECL kit, Amersham Phar-
macia Biotech, Piscataway, NJ).
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2.2.5 In-vitro functional assays
For direct comparison of different CAR constructs, normalization for transduction
efficiency was accomplished by the addition of untransduced T-cells from the same
donor to a transduction level of 20% in all constructs, or corresponding to the low-
est percentage of the constructs compared in al in-vitro assays, as per published
protocols[154].
2.2.5.1 51Cr release cytotoxicity assay
Standard 51Cr release assays were performed to determine cytotoxic activity of
CD19-CAR T cells against CD19+ cell targets, Raji and SupT1CD19 as well as
a CD19- target, supT1NT. Three x 106 target cells were labeled with 100 µCi 51Cr
(Perkin Elmer) for 1 hour, during which cells were intermittently agitated to im-
prove the uptake of 51Cr. On washing, 5 x 104 targets per well were coincubated for
4 to 5 hours with effector T cells at various effector to target (E:T) ratios, starting
from 32:1 to 2:1. Untransduced cells, which had been activated using an identical
method, served as a negative control. Target cells in complete media or lysed with
1% TritonX-100 (SigmaAldrich) were used to determine spontaneous and maxi-
mum release, respectively. Assay supernatants were counted for 51Cr release using
High Binding Isoplate-96 HB (Perkin Elmer) and a 1450 MicroBeta TriLux (Perkin
Elmer). Specific lysis was calculated as follows: % Lysis = (experimental lysis -
spontaneous lysis) / (maximum lysis - spontaneous lysis) x 100.
2.2.5.2 Long term cytotoxicity assay by flow cytometry
Effector and target cells (NALM6, SupT1-CD19 and SupT1CD19LO) were co-
cultured in triplicates in a 96-well round-bottom plate at a 1:1, 4:1 or 10:1 ratio
(total number of cells 1x105) without further addition of cytokines. At 24 hours
triplicate wells were harvested and merged into single FACS tubes for flow cyto-
metric analysis. Cells were stained for expression of CD2 and a live dead marker
was included, as an assessment of viability. Countbright beads (Thermo Fisher)
were added to allow a standardized acquisition on the flow cytometer. After the ad-
dition of Fixation buffer, cells were stored at 4◦C in the dark until analysis. Target
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cells were identified by GFP expression (NALM6) or CD2 expression (negative in
SupT1CD19 & SupT1CD19LO).
2.2.5.3 3H-thymidine proliferation assay
The 3H-thymidine incorporation assay employs a method wherein a radioactive nu-
cleoside, tritiated thymidine (3H-thymidine), is incorporated into new strands of
chromosomal DNA during mitotic cell division. The amount of radioactivity incor-
porated into DNA in each well is measured with a betacounter and is proportional
to the number of proliferating cells. The readout is counts per minute (cpm) per
well.
On day 6 after transduction, 1 x 105 transduced and untransduced effector cells
were co-cultured at a 1:1 ratio with irradiated target cells (Raji & SupT1NT) in R10
medium, without addition of IL-2 in 96-well round bottomed plates. The cells were
allowed to proliferate for a further 48 hours at 37◦C in a humidified CO2 tissue
culture incubator. 3H-thymidine was diluted in RPMI+10% FCS to a concentration
of 10 µl /ml = 10 µCi /ml. 100 µl of medium was carefully removed from each
well, so as not to disturb the cell layer as far as possible, and replaced with the 3H-
thymidine solution, resulting in a final concentration of 1 µCi/well for the final 18
hours of culture.
Cells were harvested with a Tomtec Harvester 96 MACH 3M, according to the
manufacturer’s protocol. In the harvesting step the cell material including genomic
DNA is captured into 96-format glass-fiber filtermats, using water as wash buffer.
Meltilex, a solid scintillator was then added on top before reading the samples in
the 1450 MicroBeta TriLux (Perkin Elmer).
After determining the mean of the triplicate wells, specific proliferation was
calculated as CPM (effectors+targets) - CPM effectors only - CPM targets only.
2.2.5.4 Cytokine production
Cytokine levels were determined by analysing supernatants from triplicate wells
after 48-hours of coculture of 1 x 105 effector cells with 1 x 105 target cells us-
ing a BD TM cytokine bead array according to manufacturer’s protocol. The CBA
Human Th1/Th2/Th17 Cytokine Kit can be used to measure Interleukin-2 (IL- 2),
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Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin- 10 (IL-10), Tumor Necrosis
Factor (TNF), Interferon-γ(IFN-γ), and Interleukin-17A (IL-17A) protein levels in
a single sample. The kit performance has been optimized for analysis of physiolog-
ically relevant concentrations (pg/mL levels) of specific cytokine proteins in tissue
culture supernatants. Data were analysed using FCAP Array (Softflow, Inc.). Mean
and SEM are reported.
2.2.6 Flow Cytometry
Flow cytometry acquisition was performed using a BD LSR II (BD Biosciences)
or Aria, and data analyis was performed using FlowJo vX (Tree Star, Inc., Ash-
land OR). Expression of CAR was detected by binding to recombinant CD19-rabbit
IgG1 protein that was fluorescent labelled with an aRabbit-fc secondary antibody,
or on the basis of mCherry expression. The transduced population was identified
using the following strategy: 1) FSC-A vs. FSC-W to eliminate doublets based on
FSC 2) SSC-A vs SSC-W to eliminate doublets based on SSC 3) FSC-A vs SSC-A
for a morphologic lymphocyte gate 4) Live dead vs CD3 to gate on the live CD3
cells 5) finally the CD3+ transduced+ cells, using non-transduced cells as negative
control. All FACS plots presenting CAR T cell phenotype data were pre-gated on
gated CAR+ cells. For non-transduced T cells, whole T cell populations were used
for analysis.
2.2.6.1 General staining protocol
Immunostaining of between 2x105 to 1x106 cells was performed with monoclonal
conjugated antibodies at certain dilutions stated in table 2.4.
When staining of intracellular proteins was required, the Biolegend Fix&Perm
protocol was followed.
Binding of soluble scFv-Fcs
To detect binding of soluble scFv-Fcs to tumour and T cells by flow cytometry,
supernatants were harvested from 293T cells transiently transfected with constructs
encoding the soluble CD19 scFv-Fcs. Target cells were incubated with harvested
supernatants, washed, and then stained with an anti-mouse IgG F(ab)2 secondary.
2.2. Methods 71
Binding to truncated CD19 isoforms
FMC63 and CAT scFv-fc (as described earlier) were added as primary layer
and incubated for 20mins at room temperature. A secondary layer of amuIgG2a-PE
(biolegend) was added. Binding was identified as double positivity for transgene
expression (GFP) and scFv-fc (PE)
2.2.6.2 PE QuantiBRITE CD19 expression quantification
QuantiBRITE PE tubes are designed for use with PE-labeled monoclonal antibodies
for the purpose of estimating expression levels by flow cytometry. When the Quan-
tiBRITE PE tube is run at the same instrument settings as the assay, the PE axis can
be converted into the number of PE molecules bound per cell. This assay was set up
according to the manufacturers protocol. Anti-CD19 PE Antibodies (BD, Miltenyi,
Biolegend) were first compared and titrated, to determine the concentration to sat-
urate the cell lines. Miltenyi CD19 PE (130098068) was used at a concentration of
1/10.
2.2.7 Live cell imaging
CAR+ T cells were selected for mCherry expression by cell sorting using FACSAria
III (BD) to exclude non-transduced cells affecting confocal analysis. GFP+ NALM6
cells were used as targets. Effectors and targets were co-cultured at a 1:8 ratio (total
number of cells=9x104) in R10-HEPES (Life Technologies) in triplicate wells using
a 96 well microplate with a glass base (Greiner Bio-One Ltd). DAPI was added to
the solution at a concentration of 500ng/ml, allowing identification of dead cells.
Live cell imaging was performed for 20hrs at controlled environmental condi-
tions (5% CO2 at 37◦C) on a Zeiss axiovert with Ludl motorised stage and a 10x
NA 0.25 CP-Achromat objective and Hamamatsu Orca ER camera. Multi-point
(2 points per well) 4 channel timelapse imaging was run with Volocity software.
Fluoroscence was captured with minimal excitation power and high camera gain to
minimise phototoxicity.
ImageJ (Fiji) software was used to score contact between target and effector
cells. Green and red channels were converted to binary images using extended
minima thresholding. Thresholded regions were extended by 2 pixels with binary
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dilation, and clusters split with a watershed. Regions of overlap between the thresh-
olded images were scored as contact points, and a new image produced showing
these contact points. The macro for image thresholding and production of the con-
tacts points image will be available upon publication of the paper.
The resulting image was then analysed in ICY (Open source) to assess the fre-
quency and duration of interactions between effectors and targets using the Spot
Tracking Plugin. Motility of the cells was measured by the Motion Profiler, includ-
ing min/max/avg/total displacement in pixels. Statistical analysis was performed
using SPSS Statistics 22 (IBM).
Following live imaging, cells were harvested and analysed by flow cytome-
try, permitting quantification of cell death in both control and experimental groups,
determining differences in number of DAPI- NALM6+ cells, normalized against
spontaneous cell death in negative control wells. The number of cells acquired was
standardized by the addition of counting beads.
2.2.8 In vivo anti tumour activity
2.2.8.1 Animals
All animal studies were approved by the University College London Biological Ser-
vices Ethical Review Committee and licensed under the Animals (Scientific Proce-
dures) Act 1986 (ASPA). Non-obese diabetic/ severe combined immunodeficiency/
common γ-chain knockout (NSG,female, aged 6-10 weeks) were obtained from
Charles River Laboratory (Wilmington, MA) and raised under pathogen free condi-
tions.
2.2.8.2 Irradiation
Unless otherwise stated, mice were sublethally irradiated at 2.8 Gy 1 day prior to
intravenous inoculation with tumour cells.
2.2.8.3 Intravenous injection of mice
Mice were heated for 15 minutes in a warming box to encourage vasodilatation
of the tail veins. Intravenous inoculation with 1x106 NALM6 engineered to ex-
press firefly Luciferase (F-Luc), as described earlier [133], was done in a volume
2.2. Methods 73
of 0.2ml. Engrafted mice received CAR+ T cells in a single injection with a vol-
ume of 0.2ml (dose specifically stated for each individual experiment), 7 days post
NALM6 injection, depending on experimental outline. CAR+ T cells were anal-
ysed by FACS for CAR expression one day prior to injection and were generally
injected as bulk (transduced and untransduced populations). If transduction effi-
ciencies were > 10% different, they were corrected by the addition of untransduced
cells to match the lower expressing construct.
2.2.8.4 Bioluminescent imaging of mice
To assess engraftment and antitumor activity of genetically modified human T cells,
tumour growth was evaluated by bioluminescent imaging (BLI) using the IVIS
Imaging Sytem. By intraperitoneal injection, anesthetized mice were given 150 µg
D-Luciferin Potassium Salt (Hichrom). Mice were anesthetized with isoflurane and
imaged 10 minutes after D-luciferin injection, with an exposure time of 60 seconds,
unless images were saturated, in which case the software was set to automatically
determine the exposure time. Luciferase activity was analyzed using Living Image
Software and the photon flux analyzed as photons/s/cm2/sr (Perkin Elmer).
2.2.8.5 Monitoring
Mice were closely monitored every 1-3 days for signs of xenogeneic graft-versus-
host disease and other toxicities and their weights were recorded 3 times per week.
End point predetermined by length of experiment or if animal becomes ill (evidence
by piloerection, hunched posture or loss of response to the environment). In addi-
tion, a loss in weight by 15% over 48 hours would result in the animal being culled.
To help prevent excess suffering the mouse grimace scale was used to determine
levels [155]. The 5 facial expressions, orbital tightening, nose bulge, check bulge,
ear position and whisker change were coded on a scale of 0-2. If any animal ex-
ceeded the score of 2 on any one of 5 conditions for 48 hours, it would be culled
according to the Protection of Animals Act, after which bone marrow and spleen
were investigated for presence of disease and CAR+T cells.
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2.2.8.6 Spleen & Bone Marrow preparation
After sacrifice, single cell suspensions were made of spleen and bone marrow by
maceration through a cell strainer. Red blood cells were lysed using ACK lysing
buffer (LONZA) and the cells were re-suspended in 2ml PBS.
Bone marrow was harvested from both a single femur and tibia from each
animal. The ends of the bone were removed and the contents of the bone marrow
were flushed with PBS and through a cell strainer, harvested in a 50ml falcon. Cells
were pelleted by centrifugation at 300G for 5 minutes. Red blood cells were lysed
using ACK lysing buffer (LONZA) and the cells were re-suspended in 1ml PBS.
Results were presented as disease free survival, phenotype, and absolute cell
counts.
2.2.9 Statistical analyses
All statistical analyses were performed in GraphPad Prism v7.02. Unless otherwise
stated, data were expressed as mean ± SEM. Statistical analyses of in vitro assays
were undertaken by 2-way ANOVA with donor matching and Tukey post-test for
multiple comparisons or 2-tailed Student t-test, as indicated in figure legends. Sta-
tistical significance was indicated as follows in the figures: ***P < 0.001; **P <
0.005; *P < 0.05; and NS, nonsignificant (P > 0.05).
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Specificity Clone Isotype Manufacturer Fluorochrome Dilution
CD3 UCHT1 Mouse IgG2a Biolegend PerCPCy5.5 2:100
CD3 OKT3 Mouse IgG2a Biolegend FITC 1:100
CD4 OKT4 Mouse IgG2b Biolegend APC 1:100
CD4 M-T466 Mouse IgG1 Miltenyi PE-Vio770 1:100
CD8 HIT-8a Mouse IgG1 Biolegend PE 1:100
CD8 HIT-8a Mouse IgG1 Biolegend FITC 1:100
CD8 SK1 Mouse IgG1 Biolegend BV605 1:100
CD19 HIB19 Mouse IgG1 Biolegend BV605 1:100
CD34 Qbend10 4H11 Mouse IgG1 Sigma-Aldrich APC 1:100
CD45RA H100 Mouse IgG2b Biolegend BV605 1:100
CD69 FN50 Mouse IgG1 Biolegend APC 1:100
CD95 DX2 Mouse IgG1 Biolegend BV421 1:100
CD127 A019D5 Mouse IgG1 Biolegend BV711 1:100
CD197 (CCR7) G043H7 Mouse IgG2a Biolegend APC/APC-Cy7 1:100
CD223 (LAG3) 3DS223H Mouse IgG1 eBioscience APCeFluor 780 2:100
CD279 (PD1) EH12.2H7 Mouse IgG1 Biolegend BV421 2:100
CD366 (TIM3) F38-2E2 Mouse IgG1 Biolegend BV711 1:100
anti-BCl-2 100 Mouse IgG1 Biolegend BV421 5:100
anti TNFα MAb11 Mouse IgG1 Biolegend BV421 5:100
anti IL-2 MQ1-17H12 Rat IgG2a Biolegend BV605 5:100
anti IFNγ 4S.B3 Mouse IgG1 Biolegend APC 5:100
Anti-Rabbit IgG polyclonal Goat F(ab’)2 Jackson Immunoresearch FITC 1:100
Anti-Rabbit IgG Poly4064 Donkey Biolegend BV421 1:100
Anti-V5 tag polyclonal Rabbit Abcam PerCP 5:100
Fixable viability dye Life technologies Aqua 0.5:1000
Fixable viability dye eBioscience APCeFluor 780 0.2:100
Table 2.4: Antibodies
Chapter 3
Determination of binding
characteristics of anti-CD19 single
chain variable fragments
3.1 Introduction
A large number of CARs have been described and the antigen binding domains
have most often been formed out of monoclonal antibodies derived from specific
anti-human hybridomas. The majority of these antibodies have a high affinity for
their target, binding cognate ligand with nM affinity [111, 156–158].
In the context of antigen-antibody interactions, binding affinity is the strength
of the monomeric reversible binding between an epitope and an antibody’s anti-
gen binding site, typically described by the equilibrium dissociation constant (KD).
The (KD) can further be described by the association rate, or the on-rate (ka), and
the dissociation rate, the off-rate (kd) and measures the propensity of an immune-
complex to fall apart into its component molecules an antibody and antigen and can
be described by the following equations:
KD =
kd
ka
=
koff
kon
=M (3.1)
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ka =Msec−1 (3.2)
kd = sec−1 (3.3)
The half life (t1/2) for the interaction is derived from the off-rate:
t1/2 =
ln(0.5)
−kd (3.4)
kd and ka are reciprocally related and can alternatively be calculated from the fol-
lowing:
ka =
[AbAg]
[Ab] [Ag]
=
kon
koff
=
1
KD
=M−1 (3.5)
Thus, is it possible for two antibodies to have the same affinity, but for one to have
both a high on- and off-rate constant, while the other may have both a low on- and
off-rate constant.
To understand the affinity of the interaction between the different scFvs and
CD19, Biacore surface plasmon resonance (SPR) measurement was used to deter-
mine the binding kinetics between these two proteins. SPR biosensors, such as the
Biacore T200, monitor the reversible interactions of proteins and detects in real time
the kinetics of the association and dissociation as the protein absorbs and desorbs
(fig 3.1). The soluble scFv-fc, derived from the anti human CD19 mAb, is immo-
bilized onto the surface of the chip and soluble CD19-antibody is flown over the
surface at a constant rate.
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Figure 3.1: SPR Biacore
The instrument measures the mass bound to the surface by a spectroscopic phenomenon. The chip is covered by gold, and
covalently coupled to goat anti-mouse IgG, onto which the CD19 scFv-fc is then linked. After immobilisation, the target -
soluble recombinant CD19 - applied in the solution forms a complex with the scFv. Upon binding, the local refractive index
will change and this has an effect on the plasmon waves, resulting in a shift of the resonance angle (α). This change in angle
is proportional to the mass bound to the chip’s surface.
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The instrument measures the mass bound to the surface by a spectroscopic phe-
nomenon. The chip is covered by gold, and covalently coupled to goat anti-mouse
IgG, onto which the CD19 scFv-fc is then linked. After successful immobilisation,
the target - soluble recombinant CD19 - is applied in the solution and will then form
a complex with the scFv. Upon binding, the local refractive index will change and
this has an effect on the plasmon waves, resulting in a shift of the resonance angle.
This change in angle is proportional to the mass bound to the chip’s surface.
Published clinical studies use T cells expressing CARs specific for CD19 in-
corporating antigen binding domains that are derived from different anti-human
CD19 hybridomas. The choice for a specific hybridoma has been pragmatic and
potentially economically driven, as a new binder is patentable. The influence of
the affinity of different CD19-targeting CARs on the downstream functionality of T
cells in responses against CD19+ targets has not yet been clearly delineated.
In 10% to 20% of cases of paediatric B-ALL treated with CD19-directed im-
munotherapy treatment failure occurs due to relapse associated with epitope loss
[86]. De novo genomic alterations in the CD19 gene found to primarily affect
exon 2, leading to a N-terminal truncated CD19 ∆ex2 isoform [95]. This mutant
bypasses recognition by CAR T cells and was reported in studies using differ-
ent CD19-targeting CARs with different binding domains and different costimu-
latory domains, and seemed to be independent of expansion or clinical protocol
[85, 88, 97, 159, 160]. The binding site on CD19 of our binder derived from CAT
hybridoma, has not yet been identified.
3.1.1 Aims
• To characterise the equilibrium dissociation constant, determined by on- and
off-rate of 6 hybridoma derived murine anti-human CD19 scFvs
• To identify the epitope binding site of CAT scFv on CD19
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3.2 Results
3.2.1 Kinetic properties of aCD19 binders varied and are pre-
dominantly determined by off-rate
We set out to compare 6 different anti human CD19 binders derived from different
hybridomas, of which 4 are taken forward in clinical trials:
• CAT
• SJ25C1
• FMC63
• B4
• 4G7
• HD37
All 6 CD19 binders were cloned in an scFv-fc format, as illustrated in figure 1.5.
This allowed linking to goat anti-mouse IgG, covalently coupled to the surface
of the Biacore chip. Soluble protein was expressed and quantified by ELISA. To
date we have not been able to express SJ25C1 as a CAR or scFv-Fc. This is most
likely caused by an error in the published sequence, showing a repeated tyrosine-
phenylalanine insertion before the conserved cysteine in framework 3 of the light
chain (see table 1.4). It is unusual to see an amino acid insertion at this framework
position, so we believed that it was an error in the sequence from the original paper.
SPR analyses for binding to CD19 were performed to assess the 5 different
aCD19 binders. In this system, binding curves associated with different concentra-
tions of CD19, injected in subsequent measurement cycles, are normalized to the
same baseline. Two individual experiments were conducted, resulting in very sim-
ilar data, one representative experiment is described in table 3.1 and displayed in
figure 3.2. Figure 3.2 visualises the ka and kd on its respective axes. The CAT scFv-
fc showed substantially lower (> 100 fold) binding affinity. A higher KD(0.116µM)
was the result of a much quicker off-rate (7.07x10−2 M-1s-1) (table 3.1). Interest-
ingly the on-rate of CAT scFv-fc was comparable to the strongest binder FMC63.
HD37, B4 and 4G7 scFv-fcs all have relatively high affinities based on their low Kd
values, but all three show a slower on-rate.
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Figure 3.2: Kinetic binding constants of anti-CD19 scFv-fcs determined by SPR Biacore
Constants plotted on a ka versus kd plot, showing the interactions of the different scFvs, derived from anti-CD19 hybridomas,
with recombinant soluble CD19 protein. KD values were calculated according to equation 3.1 and ranged from 8.8e-10 to
1.1e-7
scFv On-rate ka (M−1sec−1) Off-rate kd(sec−1) Dissociation constant KD (nM)
HD37 1.73e+05 4.55e−04 2.63
B4 1.62e+05 8.96e−04 5.52
FMC63 6.24e+05 5.50e−04 0.881
CAT 6.09e+05 7.07e−02 116
4G7 6.01e+04 1.21e−03 20.1
Table 3.1: Kinetic binding variables of anti-CD19 scFv-fcs determined by Biacore kinetic
screening
Kinetic and equilibrium dissociation constants of the CD19 binders derived from HD37, B4, FMC63, CAT & 4G7 hybridomas
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3.2.2 Investigation of the affinity of FMC63, 4G7 and CAT scFv-
fc by Scatchard analysis
Since SPR assays are based on recombinant protein binding, we sought to cross-
reference the binding data of FMC63, 4G7 and CAT in scFv-fc format by flow
cytometry, based on their distinct kinetic properties. For this experiment the affinity
against target cells that naturally express CD19 on their cell surface (Raji) was mea-
sured. The conventional method for measuring the affinity of an antibody for a sur-
face antigen is by Scatchard analysis. Scatchard analysis is a method of linearizing
data from a saturation binding experiment in order to determine binding constants.
One creates a secondary plot of specific binding/free ligand concentration (y-axis)
vs. specific binding (x-axis). The slope of this line equals -1/KD. Scatchard anal-
ysis revealed an affinity of the different scFv-fcs to CD19+ Raji cells that reflected
our SPR results, again showing a > 100 fold reduction in binding strength of CAT
scFv-fc compared to FMC63 scFv-fc (fig 3.3 B-D).
CD19+ target cells, Raji cells (1x106/ml) were serially diluted and incubated
with different concentrations of anti-CD19 scFv-Fc, and allowed to equilibrate,
prior to flow cytometric analysis of scFv-Fc binding to the cells. The Scatchard
analysis, as shown in figure 3.3, showed that FMC63 scFv-Fc bound to CD19 on
Raji cells at significantly lower concentrations (< 5x10−10M) than 4G7 and CAT.
For FMC63 and 4G7 binding plateaued at 2.5x10−9M and 1x10−8M respectively.
No such saturation of binding was seen with CAT, which is indicative of a high KD
value or low affinity. A non-linear regression analysis was performed to fit the curve
and determine KD values.
Although the absolute KD values obtained using either SPR Biacore of
Scatchard methods, are not directly comparable, having been derived differently
measuring the binding between different compounds, these results do confirm that
the relation between the affinities of the different scFv-fcs, showing a > 100 fold
difference between FMC63 and CAT, as measured by Biacore, seems to be simi-
lar, when targeting an antigen on the cell surface (FMC63 scFv-fc SPR 0.88 nM vs
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Figure 3.3: Determination of affinity of FMC63, 4G7 and CAT scFv-fcs for cell-bound CD19
using Scatchard analysis
Scatchard analysis is a method of linearizing data from a saturation binding experiment in order to determine binding con-
stants. The slope of the straight line equals −1/KD from which KD was calculated.(A) Saturation Binding Curves. Scatchard
of (B)FMC63 scFv-Fc (C) 4G7 scFv-Fc (D) CAT scFv-Fc
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Scatchard 0.2nM, 4G7 scFv-fc SPR 20nM vs Scatchard 1nM and CAT scFv-fc SPR
116nM vs Scatchard 28nM).
3.2.3 Binding of CAT and FMC63 scFv-fc to truncated protein
isoforms of CD19
The distance between the CAR-bound epitope and the target cell membrane influ-
ences the synapse formation between the CAR-expressing T cell and target. CD19
is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily con-
taining two extracellular immunoglobulin(IgG)-like domains and an extensive cy-
toplasmic tail. We constructed the full length peptide and three variants with in-
creasing truncation of CD19 (∆ ex2, ∆ ex2-3, ∆ ex2-3-4), including a V5 tag under
the signal-peptide (Fig. 3.4). The V5 tag allowed us to verify if the protein was
expressed on the cell surface, which had to be confirmed prior to study potential
binding of our different scFv-fcs to the truncated isoforms of CD19. The truncated
CD19 isoforms were expressed on 293T cells by transient transfection. In addition,
transgene expression was identified by GFP expression.
In the study by Sotillo et al. two isoforms were described, ∆ ex2 and ∆ ex5-6.
∆ ex5-6 is completely cytosolic, lacking both transmembrane and extracellular do-
mains. In addition, they reported that the ∆ ex2 CD19 isoform is also largely cytoso-
lic, unlike full-length CD19, which localizes exclusively to the plasma membrane
[95], but based on confocal microscopy protein/cell membrane co-localization scor-
ing a small fraction (less than 10% of total) did appear to make it to the cell mem-
brane.
By flow cytometry we were unable to detect any of the truncated isoforms
expressed on the cell membrane, despite demonstration of successful transfection
on the basis of GFP expression, as shown in the upper row of figure 3.6. Western
blot analysis of the total cell lysates expressing the different isoforms confirmed
presence of the protein (Fig. 3.5). We therefore repeated the staining for V5, this
time on permeabilized cells and, albeit at low levels, were able to detect V5, as
shown in the lower row of figure 3.6. This was important for further analysis of the
binding of FMC63 and CAT scFv on the truncated isoforms of CD19, because it
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(a)
(b)
(c)
(d)
Figure 3.4: CD19 truncated isoforms
The truncated CD19 variants were expressed by 293T cells in order to investigate the binding epitope
location of FMC63 and CAT scFvs. The predicted CD19 proteins encoded by the full-length (FL)
(A) and the truncated ∆ex2(B), ∆ex2-3(C), ∆ex2-3-4(D) isoforms of CD19. The epitope recognized
by CD19-CAR T cells is encoded by a sequence contained within exons 1-4. The transmembrane
domain is encoded by exons 5 and 6.
Adapted from [95]
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confirmed presence of the protein at least in the cytosol. The 293T cells were again
permeabilized and we performed binding studies on truncated variants of CD19. By
a secondary staining, targeting the murine Fc component of the scFv-Fcs, binding
of both FMC63 and CAT scFv-fc to wild type CD19 showed 16.8% and 16.1% dual
positivity respectively (exon 2, Fig. 3.7). Of note, the higher MFI of FMC63 scFv
(MFI 3651, in figure 3.7 as compared to CAT scFv (MFI 1372) is in line with the
previous Scatchard analysis discussed in section 3.2.2, confirming higher levels of
binding of FMC63 to CD19 and consistent with its higher affinity. No binding of
either FMC63 or CAT scFv-Fc to exon 2 truncation mutants was seen, suggesting
both bind this region of CD19.
Figure 3.5: Western Blot of CD19 truncated isoforms transiently expressed on 293T cells.
Western blot analysis of lysed 293T cells confirmed presence of the different truncated isoforms of CD19. Bands represent
detection of protein by binding of aV5 antibody. Sizes corresponded to expected length of glycosylated protein [95]
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3.3 Discussion
In chapter 1, we highlighted that in natural T cell interactions the binding and in-
teraction of the TCR with a specific pMHC is pivotal in regulating the activity and
specificity of the T cell. Although higher affinity interactions increase specificity for
a ligand, a threshold of affinity has been described, as T cell functional avidity can
be detrimentally affected when dissociation is prolonged [31]. In contrast to the nat-
ural TCR, CARs employ a different mechanism by which they recognize antigens
in an MHC-independent manner. CARs, through their scFv, recognize membrane-
bound cell surface antigen typically with a much higher affinity (KD= 80-1 nM)
compared to TCR-pMHC affinity (KD=10-1 µM) [143], and are commonly derived
from high affinity monoclonal antibodies (mAbs) cloned from hybridomas.
To date, different scFvs targeting CD19 have been used in CARs taken forward
in clinical trials. Relative to the previously published affinities of different binding
domains used in CAR design, typically ranging between 1-10nM, 4 out of 5 of our
CD19 binding domains show similar binding strengths, ranging between 0.8-20nM.
We have generated a novel CD19-CAR, derived from a different murine anti-human
CD19 hybridoma (CAT CAR) [161]. CAT scFv has a fast on-rate, forming a sim-
ilar amount of complexes per second with CD19 compared to FMC63, however
displaying a much quicker off-rate, releasing off its target in only a matter of sec-
onds, resulting in a much lower affinity of 118nM.
Although some studies have addressed the impact of binding domain affinity
on CAR T cell functionality [146, 147, 151, 152], none of these binding domains
were reported to have such a quick off-rate. In addition, the fact that CAT scFv on-
rate is very similar to FMC63 scFv gives us the unique opportunity to specifically
study the impact of the dissociation constant on CAR T cell functional avidity.
Binding of CAT and FMC63 scFv-fc to truncated protein isoforms of CD19
expressed by 293T cells show both bind to an epitope contained within exon 2. This
suggests that differences in synapse width are unlikely to contribute to differences
in response of T cells bearing the FMC63 or CAT CARs.
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We were unable to stably express the CD19 truncated isoforms on the cell sur-
face, but instead showed these proteins were located in the cytosol. After personal
communication with Elena Sotillo [95], one possible explanation for their observed
“expression” of CD19 truncated isoforms on the cell surface was the use of an ex-
pression vector that resulted in unphysiological high expression levels, that may
have resulted in leakage of the protein from the cytosol to the cell surface. This
has significant clinical relevance, as the frameshift mutations clustered in the non-
constitutive exon 2 eliminate full-length CD19, but allow expression of the ∆ ex2
isoform in the cytosol, as a result, the mutated CD19 cannot be effectively targeted
by CAR T cell immunotherapy because of its general restriction to targeting of cell
surface molecules.
Chapter 4
In vitro characterization of
FMC63-CAR+ and CAT-CAR+ T
cells
4.1 Introduction
In chapter 3 we characterised the binding affinities of scFvs derived from 5 anti-
CD19 hybridomas (FMC63, CAT, 4G7, HD37, B4). The influence of the affinity
and differing binding kinetics of different CD19-binding domains on the down-
stream CAR T cell functionality in response to CD19+ targets has not yet been
delineated. We next sought to investigate the impact of scFv affinity, on CAR T
cell function in vitro and in particular of the off rate, by incorporating different
anti-CD19 scFvs into an identical second generation 41BBZ CAR backbone, as il-
lustrated in figure 4.1. We focused particularly on FMC63 and CAT as we have
shown that these bind epitopes expressed on exon 2 of CD19 with distinct affini-
ties and binding kinetics (Figure 3.7 and section 3.2.3). The fact that the difference
in affinity between CAT and FMC63 (KD FMC63 0.881nM and CAT KD 116nM)
is solely contributed to by an increased off rate (kd FMC63 5.5x10−4 and kd CAT
7.07x10−2) in the setting of a near identical on rate (ka FMC63 6.24x105 and ka
CAT 6.09x105) provided an opportunity to dissect the relative contributions of these
binding variables to downstream CAR T cell function.
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4.1.1 Aims
• To investigate the impact of scFv affinity, and in particular of the off rate,
by incorporating FMC63 and CAT anti-CD19 scFvs into an identical second
generation 41BBZ CAR backbone.
• To phenotypically characterize T cells transduced with the different affinity
CD19 CARs.
• To investigate CAR+ T cell functional responses, using in vitro functional
assays, studying proliferation, differentiation, target cell killing, and the pro-
duction and secretion of effector cytokines.
• To perform live cell imaging, to investigate the impact of differences in CAR
affinity on interactions between CAR T cells and their targets on a micro-
scopic level.
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4.2 Results
4.2.1 Expression of Chimeric Antigen Receptor is identified by
transgene expression and binding to recombinant CD19
soluble protein.
Second generation CARs differing only in their aCD19 scFv, from either the
FMC63 or CAT hybridoma, linked to a CD8 transmembrane domain, a CD137
(4-1BB) costimulatory domain, and a CD3 ζ-signalling domain were expresssed in
primary human T cells by lentiviral transduction after activation with CD3/CD28
beads (detailed description in section 2.2.2.7). Figure 4.1 shows the schematic
representation two different anti-CD19 scFvs into an identical second generation
41BBZ CAR backbone.
Figure 4.1: Schematic representation of anti-CD19 CAR
Both constructs contain an aCD19 scFv, from either the FMC63 or CAT hybridoma, a CD8 transmembrane domain, a CD137
(4-1BB) costimulatory domain, and a CD3 ζ-signalling domain.
We first sought to evaluate the surface expression of CAR on T cells after trans-
duction using the pCCL.PGK lentiviral vector. The pCCL-aCD19 scFv-41BBZ
lentiviral vector encodes the pCCL lentiviral backbone, in which the enhancer and
promoter of CMV are joined to the R region of HIV-1 and the aCD19 scFv-41BBZ
CAR. A schematic representation of the vector is given in figure 2.1. The mCherry
gene was coexpressed with CAR by cloning it upstream of the CAR separated by
an in-frame 2A ribosomal skipping sequence.
Transduction efficiency was found to be donor dependent, ranging from 20-
60% as assessed by mCherry expression. Representative FACS plots illustrating
the two detection methods used to determine transduction efficiency of FMC63 and
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CAT CAR constructs are displayed in figure 4.2. CAR expression was detected
by binding to a recombinant CD19 protein-Fc construct and correlated well at a
1:1 ratio with mCherry consistent with the presence of an in-frame 2A ribosomal
skipping sequence [162]. As expected, the mean fluorescence intensity (MFI) for
FMC63 was higher than for CAT with the tagged CD19 protein, whereas mCherry
expression was similar.
In order to ensure differences seen resulted only from the differing binding
kinetics of the CARs, we corrected the number of CAR transduced T cells, taking
into account relative transduction efficiency when the difference between constructs
exceeded 10%. Donor-matched non-transduced cells were therefore added, to nor-
malise transduction efficiency to the lowest transduction level in all constructs in
all in-vitro assays, as per published protocols [154]. Transgene expression levels
were comparable between the two constructs, showing no significant difference in
mCherry MFI (fig. 4.3) (MFI FMC63 2476, MFI CAT 2132 in representative FACS
plot), but a lower MFI for rCD19 in CAT CAR, in accordance with its lower affinity
for CD19 (MFI FMC63 7680, MFI CAT 4831). As CAR T cell avidity is influenced
by the receptor expression density, it was critical to establish comparable levels of
CAR expression in both constructs compared.
Figure 4.2: Transduction efficiency of activated CD3/CD28 bead-expanded human T cells
Transduction efficiency of PBMCs lentivirally-transduced to express FMC63 and CAT CAR constructs. The panel shows
detection of CAR using mCherry transgene expression and a recombinant CD19 protein with an Fc tag construct. Data are
representative of >20 independent experiments. (Median fluorescence intensity (MFI) of mCherry FMC63 2476, CAT 2132.
MFI for rCD19 FMC63 7680, MFI CAT 4831 in representative FACS plot).
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Figure 4.3: mCherry transgene expression levels of FMC63 and CAT CAR-transduced T
cells measured by flow cytometry
MFI of mCherry transgene expression levels of FMC63 and CAT CAR-transduced T cells was determined 7 days-post trans-
duction by flow cytometry,statistical comparisons were made with a two-tailed paired Student t-test, NS = not significant,
n=9
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4.2.2 Phenotype of T cells transduced with FMC63 and CAT
CAR
Figure 4.4:
Characterization of T cell memory
compartments
To determine if the different affinity binding domains
impacted T cell phenotype, we analysed CAR trans-
duced T cells for their expression of CD45RA and CCR7
as markers for differential memory subsets, as illustrated
in figure 4.4. Human T cells can be divided into at
least four different subsets, based on their phenotype and
functions: naive (Tnaive, CCR7+ CD45RA+) and cen-
tral memory (TCM, CCR7+ CD45RA-) T cells display
high proliferative potential and lack of an immediate ef-
fector functions whereas effector memory (TEM, CCR7-
CD45RA-) and CD45RA+ effector memory (TEMRA, CCR7- CD45RA+) T cells
have low proliferative capacities but produce cytokines and exert cytotoxic activity,
respectively [163]. CD45RA+ effector TEMRA cells represent the most differenti-
ated type of memory cells and have a high susceptibility to apoptosis. From a TCR
perspective it is known that TCR affinity and t1/2 of the pMHC-TCR interaction in-
fluence memory fate [164] and effector memory T cells are favoured by strong TCR
signalling [165]. It has recently been shown that the proliferative capacity of mem-
ory CD8+ T cells following antigen clearance progressively increases with time both
in the TCM and TEM subpopulations, but is most prominent among TCM cells [166].
Which T cell subsets should be utilized for adoptive immunotherapy has been de-
bated for many years. TCM however have been associated with long-term CAR+ T
cell therapeutic efficacy due to their ability to achieve long-term persistence in vivo
and a greater proliferative capacity upon antigen-reencounter[166].
We hypothesized that prolonged antigen ligation in FMC63 CAR transduced
T cells could lead to a more pronounced differentiation into TEM cells and poten-
tially TEMRA cells. To investigate this, T cells were rested for 8 days following
transduction, after which they were stimulated with irradiated CD19+ target cells
(Raji) at a 1:1 ratio and kept in culture for another 7 days, without further addition
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of cytokines. Representative FACS plots of the different memory compartments
identified are displayed in figure 4.5. The difference in scFv did not result in an
alteration of the proportion of effector memory and central memory T cells found
after in vitro expansion in the presence of antigen, as shown in figure 4.6. To deter-
mine the effect of proliferation on the different memory compartments after antigen
specific stimulation, T cells transduced with FMC63 or CAT CAR were compared
by absolute number in each compartment (TCM: FMC63 5.6x105± 1.9x105, CAT
6.4x105± 2.0x105; TEM 3.6x105± 1.2x105, CAT 3.9x105± 9.2x104). In contrast,
there was limited persistence and proliferation of untransduced T cells following
stimulation. Collectively, these data suggest that FMC63 and CAT CAR+ T cells,
co-cultured with CD19+ targets, demonstrate proliferation upon antigen specific
stimulation and equivalent proportions of central and effector memory phenotype T
cells, suggesting that prolonged binding of FMC63 CAR T cells to CD19 target in
vitro does not lead to differentiation into a more terminally differentiated phenotype.
(a) (b)
Figure 4.5: Representative FACS plots of CAR+ T cell memory compartments analysed by
flow cytometry
Distribution of CAR+ T cells between the different memory T cell subsets at 7 days post activation with irradiated CD19+
target cells (Raji) at a 1:1 ratio. Representative FACS plots of 3 independent experiments in 5 different donors show (A)
CAR+ T cell phenotype eight days post-transduction without antigen stimulation (B)CD19+ antigen stimulated CAR+ T cell
phenotype, 7 days after stimulation, without any further addition of cytokines.
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Figure 4.6: Distribution of absolute numbers of CAR+ T cells within different memory sub-
sets 7 days post stimulation
Eight days post transduction 1x105 CAR+ T cells and untransduced T cells were stimulated with irradiated Raji cells at
a 1:1 ratio and left in culture for another 7 days, without addition of cytokines. Absolute number of TCM: FMC63
5.6x105 ± 1.9x105, CAT 6.4x105 ± 2.0x105; TEM 3.6x105 ± 1.2x105, CAT 3.9x105 ± 9.2x104. Data represented as mean
±SEM, n=4
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4.2.3 Antigen induced receptor downregulation
The serial triggering model of TCR stimulation is based on the assumption that one
pMHC sequentially engages several TCR molecules to obtain a threshold for T cells
activation [31]. Rapid downregulation of the endogenous TCR can occur during the
process of activation, within the time scale of 1/koff, and is considered a parameter
for TCR occupancy and serial triggering, which is influenced by the strength of TCR
binding and relates to biological response [34, 167, 168]. CAR downregulation has
also been described, but the effect of affinity on CAR downregulation is unknown
[77, 145].
On the assumption that the quick off rate of CAT-CAR+ T cells would benefit
serial triggering we sought to determine the propensity for antigen-induced CAR
downregulation. To investigate this, CAR+ T cells were co-cultured with CD19+
Raji cells and CD19- SupT1 NT and CAR expression was analysed 7 days after the
start of co-culture. Density of CAR expression, represented by MFI, was measured
by flow cytometry as shown in figure 4.7. Our data show that whereas expression
of the two CARs was comparable following stimulation with CD19- SupT1 NT
cells, following stimulation with Raji, T cells expressing CAT CAR demonstrated
a reduction in MFI at 7 days post-co-culture relative to FMC63 CAR transduced T
cells, (MFI anti-rabbit Fc FITC following Raji stimulation: CAT transduced cells
1164 ± 181.2, FMC63 transduced cells 1981 ± 263.6). These results suggest that
the greater receptor (CAR) downregulation in T cells expressing CAT CAR com-
pared to FMC63 may reflect a greater propensity for serial triggering, which we
would hypothesise may be related to its faster off-rate. In contrast, CAR expression
after co-culture with a CD19 negative target remains unchanged and was not sig-
nificantly different between the CAR T cell populations demonstrating this effect is
dependent on interaction of the scFv domain with of CAR with CD19+ antigen.
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Figure 4.7: CAR T cell surface expression of FMC63 and CAT CAR following CD19 antigen
positive and negative stimulation
CAR surface expression levels on T cells was determined following co-culture with CD19+ and CD19- targets (Raji & SupT1
cells at 1:1 effector:target ratio) as determined by binding to rec-CD19-Rbfc protein, followed by a secondary anti-rabbit fc
staining. MFI aRbfc FITC following Raji stimulation: CAT transduced cells 1164 ± 181.2, FMC63 transduced cells 1981 ±
263.6, Student t-test, n=3, * p< 0.05
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4.2.4 Lower CAR affinity in the context of a faster off-rate does
not result in reduced antigen-specific responses and is as-
sociated with enhanced proliferation
To investigate whether lower CAR affinity in the context of a faster off-rate would
result in reduced antigen specific responses, we studied antigen specific prolifera-
tion of FMC63 and CAT CAR transduced T cells, and their production and secretion
of effector cytokines.
4.2.4.1 Cytokine production
Differences in cytokine production may have important consequences both for the
functionality of the CAR+ T cells and toxicity when used clinically. To compare
their functionality supernatants were harvested 48 hours after 1:1 stimulation of
FMC63 and CAT CAR transduced T cells from the same donors (n=4) with Raji
cells and analysed by cytokine bead array analysis. There was a significantly greater
production of TNF-alpha (Mean concentration ± SEM: CAT CAR T cells: 750.7
± 103.3 pg/ml, FMC CAR T cells: 292.1 ± 36.51 pg/ml, n=4, p<0.01) and a trend
towards greater production of IL-2 in CAT CAR transduced T cells (Mean concen-
tration ± SD CAT CAR T cells: 11156 ± 2777 pg/ml, FMC63 CAR T cells: 5501
± 1285 pg/ml, n=4, p=0.11) (Fig. 4.8). T cell activation is associated with the
release of pro-inflammatory cytokines. Following activation with CD3/CD28 dyn-
abeads the CAR T cells have matured towards a Th1/Tc1 phenotype, as identified
by the production of TNF-alpha, IFN-gamma and IL-2 [169]. This was seen in both
CARs after CD19 specific activation by Raji cells. The greater production of TNF-a
lpha and IL-2 may reflect enhanced activation as a result of serial triggering in CAT
CAR transduced T cells.
4.2.4.2 3H-thymidine proliferation assay
To further investigate the impact of CAR binding affinity on the effector functions
of the CAR T cells, we compared the antigen specific proliferative response, mea-
sured by 3H-thymidine uptake after stimulation of CAR expressing T cell popula-
tions with two different cell lines that naturally express CD19 (Raji and NALM6)
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in 5 donors. As illustrated in figure 4.9, 3 days after antigen stimulation, in the ab-
sence of exogenous cytokines, CAT CAR transduced T cells showed a significantly
greater proliferative response to both CD19+ targets (Mean CPM ± SEM: Raji:
CAT CAR T Cells 63158±7159, FMC63 CAR T cells 27582±2776, n=4, p<0.01;
NALM6: CAT CAR T cells 49237±14006, FMC63 CAR T cells 13097±4047).
Taken together with the greater Th1 cytokine production observed this suggests T
cells transduced with the low affinity CAT CAR may show enhanced functional
avidity in response to CD19+ targets.
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Figure 4.8: Quantification of cytokine production by Cytokine Bead Array of FMC63 and
CAT CAR+ T cells following CD19+ stimulation
Production of cytokines in response to 1:1 co-culture with irradiated Raji cells measured by Cytokine Bead Array of culture
supernatants taken at 48 hours. Data, mean ± SEM, n=4; **, P<0.01; NS, non= significant, statistical comparisons were
made with a two-tailed paired Student t-test.
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Figure 4.9: CAT+ CAR transduced T cells exhibit enhanced functional avidity compared to
FMC63 transduced T cells determined by proliferative response following CD19+ stimulation
Proliferation, as measured by the incorporation of 3H-thymidine following a 72 hour 1:1 co-culture
with irradiated CD19 positive (Raji & NALM6) and CD19 negative (SupT1) cell lines. Data, mean
± SEM, n=5; *, P<0.05, ** p<0.01, statistical comparisons were made with a two-tailed paired
Student t-test
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4.2.5 Neither FMC63 nor CAT CAR transduced T cells exhibit
an exhausted phenotype following CD19 specific stimula-
tion
Although functional effector T cells can transiently express inhibitory receptors dur-
ing activation, prolonged and/or high expression of multiple inhibitory/activation
receptors is a key feature of the exhaustion of CD8+ and CD4+ T cells [170]. To
assess the effect of CAR binding affinity on T cell exhaustion, we compared the
expression of PD-1 and TIM3 on FMC63 vs CAT CAR transduced T cells from 5
donors 7 days after the start of a 1:1 co-culture with irradiated Raji cells. As shown
in figure 4.10, the pattern of inhibitory-receptor co-expression was comparable be-
tween both FMC63 and CAT CAR transduced T cells. There was a small proportion
of T cells expressing both PD1 and TIM3, which as a combination is indicative of
exhaustion (FMC63 4.4% ± 1.3, CAT 7.4% ± 3.3, n=4). Single expression of both
PD1 and TIM3 was also comparable (FMC63 PD1+ 17.2% ± 11.6, CAT PD1+
19.3% ± 10.6; FMC63 TIM3+ 45.8% ± 24.3, CAT TIM3+ 37.8% ± 21.0). Singu-
lar expression of either PD1 or TIM3 alone may reflect activation of the CAR+ T
cells, following antigen specific stimulation.
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(a)
(b)
Figure 4.10: Expression of activation/exhaustion markers on CAR transduced T cells follow-
ing CD19+ stimulation
Expression of activation & exhaustion markers 7 days after 1:1 stimulation with irradiated Raji cells
measured by flow cytometry for PD1 and TIM3 gated on CAR+ T cells. (A) Representative FACS
plots of PD1 and TIM3 expression on FMC63 and CAT CAR transduced T cells (B)Cumulative
data on exhaustion marker expression analysed by flow cytometry. Data represented as mean ±
SEM,n= 5
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4.2.6 T cells transduced with a lower affinity anti-CD19 CAR
demonstrate a greater cytotoxic capacity
To further characterize the antitumour activity of CARs, we assessed their ability to
kill different tumour cell lines in-vitro using a standard 4hr 51Cr release cytotoxicity
assay in 5 donors. The target cell lines employed were a T cell lymphoma cell line
(SupT1) that was engineered to express CD19 and Raji, a Burkitt lymphoma cell
line that naturally expresses CD19. Resting transduced and non-transduced T cells
were used as effector cells.
We observed CD19 specific cell lysis induced by both the FMC63 and CAT
CAR+ T cells, as shown in figure 4.11. However at all E:T ratios, the relative
cytolysis of T cells bearing CAT CAR against SupT1 CD19 was greater than those
bearing FMC63 CAR. This effect was more apparent at low E:T ratios (at 0.8:1
11% in FMC63 CAR T cells vs 20% in CAT CAR T cells).
The relatively small difference between the observed maximal lysis at an E:T
of 0.4:1 (13%) and that observed at E:T of 0.8:1 (20%) may indicate that CAT+
T-cells lyse more than one target cell, and could potentially explain an improved
ability to serially kill as compared to the high affinity binder FMC63. No lysis
was observed with non-transduced T cells and similarly neither FMC63 nor CAT
transduced T cells killed SupT1NT cells, demonstrating the antigen-specific nature
of cytotoxicity.
A similar trend was seen against Raji cells, however unexpectedly, the cyto-
toxic activity of T cells transduced with both CARs against this cell line was sig-
nificantly lower than anticipated. We have tried, by using freshly thawed cells and
changing the passaging schedule of the cell line, to increase the chromium uptake
of these cells, but this did not result in any improvement. As the cytotoxic activity
was consistently low, after having repeated the assay multiple times, we hypothe-
sized that the 4 hour incubation is insufficient for CAR T cells to effectively lyse
the Raji cells. In a separate experiment where we co-cultured effectors and targets
for 24 hours we showed that indeed CAR T cells transduced with either construct
were able to effectively lyse Raji cells (data not shown).
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(a)
(b)
(c)
Figure 4.11: CAR+ T cells demonstrate efficacious and antigen-specific killing of CD19+
tumour cells measured by standard 4-hour 51Chromium release assay.
CAR+ T cell cytotoxic activity against (A) Target antigen negative supT1NT (B) SupT1 cells that are engineered to express
CD19 (SupT1CD19) (C) Raji cells, a Burkitt lymphoma cell line that naturally expresses CD19 . Plots show mean % lysis
SE, n= 5; *, P<0.05,statistical comparisons were made with a 2-way ANOVA.
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4.2.7 Long term cytotoxicity assay
Given our findings of receptor downregulation, as an indicator of potential serial
triggering in CAT CAR transduced T cells (as described in section 4.2.1), and the
results of the 51Cr release cytotoxicity assay, we hypothesised that changes in CAR
affinity may not only result in serial triggering but also serial killing.
Indeed CAR T cells have been shown to serially kill multiple targets [171].
Davenport et al. show that at low E:T ratios the tumour cell killing rate was similar
via TCR or CAR ligation over the first 20 hours of coincubation. However, from 20
to 50 hours, tumour cell death mediated through CAR became attenuated. They do
not provide data on the binding affinity of the TCR or CAR compared in this study.
We hypothesize though that the capacity of CAR transduced T cells to undertake
serial killing may also be dependent on interaction half-time.
To test this hypothesis in the CAR transduced T cells, we set up a flow cytom-
etry based cytotoxicity assay against two different cell lines: (i) NALM6, naturally
expressing CD19, (ii) SupT1CD19LO, a cell line engineered to express CD19 at
very low levels. Experimental parameters were altered by reducing the E:T ratio to
1:10, in order to uncover serial killing activity of multiple targets by CAR T cells,
which might not otherwise be determined under standard conditions for cytotoxicity
assay.
First, the absolute levels of CD19 expression on several cell lines were quanti-
fied, as displayed in figure 4.12. CD19 expression levels on SupT1CD19 LO cells
are approximately 150-fold lower than the naturally expressing cell lines, NALM6,
Raji and B-cells (Absolute CD19 mAb bound/cell: Raji 3014, NALM6 2285, B
cells 3018, SupT1 CD19LO cells 140).
Next, FMC63 and CAT CAR transduced T cells were incubated with
SupT1NT, SupT1CD19LO and NALM6 targets at a 1:1 and 1:10 E:T ratio for
24 hours, as illustrated in figure 4.13. Target cells were not irradiated, to try and
mimic the natural situation where target cell proliferation may affect the CAR T
cell cytotoxic capacity. As previously observed in the 51Cr release assay, there
was no killing of SupT1NT cells. Interestingly at a 1:1 ratio, both CAT and FMC
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Figure 4.12: PE-QuantiBRITE CD19 expression quantification of different cell lines
CD19 expression levels were quantified, by the use of a PE-QuantiBRITE kit, on the following cell lines: SupT1NT: a CD19
negative T cell lymphoma cell line, SupT1CD19LO: a T cell lymphoma cell line engineered to express CD19 at very low
levels, SupT1CD19HI: a T cell lymphoma cell line engineered to express CD19 at high levels, Raji: a naturally expressing
Burkitt Lymphoma cell line, NALM6: a naturally expressing Acute Lymphoblastic Leukaemia cell line, CD3-CD20+PBMC:
PBMC gated on CD20+ B cells, CD3+ PBMC: PBMC gated on CD3+ T cells
CAR transduced cells are able to effectively kill the majority of the NALM6 (Mean
% remaining live fraction ± SEM: CAT 26.77 ± 9.472, FMC63 26.82 ± 11.17,
n=8, p=0.84, as assessed with a non parametric paired t-test ). Under more chal-
lenging conditions of reduced antigen density and/or low E:T ratios, the remaining
live target cell percentage was consistently lower after incubation with CAT CAR
transduced T cells than with FMC63 CAR T cells, but these results did not reach
statistical significance, which may reflect donor-donor variability (SupT1CD19LO
cells at a 1:1 ratio Mean % remaining live fraction ± SEM: CAT 21.08 ± 5.015,
FMC63 28.57 ± 6.621,n=8, p=0.16, SupT1CD19LO at 1:10 ratio Mean % remain-
ing live fraction ± SEM: CAT 67.98 ± 7.286, FMC63 84.23 ± 8.429,n=8, p=0.13,
NALM6 at 1:10 ratio Mean % remaining live fraction± SEM: CAT 38.61± 7.007,
FMC63 51.23 ± 9.161, n=8, p=0.16). Thus, our data do not provide evidence for
enhanced cytotoxicity against low expressing targets or serial killing of CAT CAR
transduced cells compared to FMC63 CAR T cells.
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4.2.8 Live cell imaging elucidates kinetic differences in effector-
target interactions depending on CAR binding domain
affinity
Figure 4.14:
Live cell imaging of CAR+ T cells and
NALM6 targets
Representative image of CAR+ T cells expressing
mCherry (red), NALM6 target cells expressing GFP
(green) and dead cells having taken up DAPI (blue).
A study by Bousso and his group revealed
that lower affinity pMHC-TCR interaction
leads to a distinct kinetic profile and higher
levels of motility of T cells, however when
TCR stimulation reaches a certain thresh-
old, T cells fully halt [172]. To inves-
tigate whether the low affinity interaction
of CAT CAR resulted in differences in
CAR T cell motility or the nature of ef-
fector:target interactions, FMC63 and CAT
CAR T cells from the same donor were in-
cubated with NALM6 cells at a 1:8 ratio and
two-dimensional T-cell movement was cap-
tured by confocal microscopy over an inter-
val of 20 hours (Fig. 4.14).
Real time assessment of cell death was performed after adding DAPI to the
culture media. To be able to compare and quantify interactions between targets and
different effector CAR T cells, we analysed comparable numbers of effectors and
targets per image at t=0, as shown in figure 4.15.
We observed a significantly greater number of effector:target interactions with
CAT CAR over 20 hours (mean no. of interactions± SEM: CAT 80.6358.1, FMC63
57.73±37.5, n=752, p<0.001, table4.1). In addition, it appeared that CAT CAR T
cells accumulated several contemporaneous interactions with targets cells. These
were difficult to quantify, despite attempting to map overlapping effector/target cell
membranes. Interestingly, the duration of these interactions were not significantly
reduced compared to FMC63 transduced T cell (Mean duration (in frames)± SEM:
FMC63 17.46±22.0, CAT 17.75±26.1). However, we observed marked differences
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in the motility of CAT transduced T cells, which showed greater displacement over
time compared with FMC63 CAR T cells from the same donor (Mean displacement
(pixel) ± SEM: CAT 130.86±10.53, FMC63 32.25±1.497, p<0.001, table4.1).
The NALM6 cells displayed almost no movement or cell death when cultured in-
dependently. Interestingly, the number NALM6 quantified by flow cytometry by
the use of counting beads, at the end of the experiment was much lower with CAT
CAR than FMC63 CAR T cells (Absolute numbers of NALM6 targets remaining
per well after 20 hours: CAT 3980, FMC63 32970, Non-transduced 89310), sug-
gesting that the greater number of effector:target interactions and motility of CAT
CAR T cells may enhance killing in this model. Further, the fraction of live CAR
T cells after 20 hours was maintained compared to that plated out at time 0 in CAT
whereas the number of FMC63 CAR T Cells after 20 hours of coincubation were
much lower than at the initial set up (Live CAR T Cells: CAT 10920, FMC63 2870).
We hypothesize this may reflect AICD, though this was not formally assessed.
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Figure 4.15: Absolute numbers of CAR T cells and targets at t=0 under conditions of live cell
imaging
Two images per well, in triplicate wells were analysed over 20 hours. At time point zero the number of effectors and targets
were quantified (Mean number of cells ±SEM. CAR T cells: CAT 59±9.042, FMC63 46±7.155, n=6, p=NS. NALM6 cells:
CAT 313.7±49.18, FMC63 337±45.53, n=6, p=NS).
CAR Mean SEM p value
Number of Eff:Tg
interactions in
20hrs/frame
FMC63
CAT
57.73
80.63
1.497
2.119
< 0.001
Total displacement
effectors (pixel)
FMC63
CAT
32.25
130.86
11.50
10.53 < 0.001
Table 4.1: Kinetic characteristics and absolute number of interactions between CAR T cell
effectors and NALM6 target cells under conditions of live cell imaging
Two images per well, in triplicate wells were analysed /over 20 hours. Absolute number of effector/target interactions were
quantified over 20 hours (mean no. of interactions ± SEM: CAT 80.63 ± 2.119, FMC63 57.73± 1.497, n=752, p<0.001)
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4.3 Discussion
There is a growing body of evidence indicating that a greater affinity of cognate
T cell interaction does not always lead to greater T cell activation or specificity
[31, 34, 167]. Kinetic models of TCR-ligand interaction propose that the duration
of the TCR-pMHC interaction determines the functional potency. The kinetic proof-
reading model and serial triggering hypothesis, discussed in section 1.2.4.2, are not
mutually exclusive. Schmid et al. showed that that TCR/multimer off-rates directly
correlated with functional avidity (as determined by the peptide concentration re-
quire to achieve half-maximal target lysis). TCR variants with the fastest off rates
displayed poor or less efficient functional avidity (KD 14.2 µM, off-rate 1.7x10−1),
however TCR variants with the slowest off-rates (KD 15 nM, off-rate 1.13x10−3)
showed reduced killing of cognate tumour cell lines. In addition, increased TCR
affinity to the nanomolar range was associated with the loss of target cell specificity
[173].
The higher affinity of CARs as compared to TCR, leads to an interaction that
can take minutes to hours, compared to the order of seconds. CAR T cells are
therefore likely to require ligation of higher numbers of receptors simultaneously
in order to become productively activated. Avidity of CAR-transduced cells is co-
determined by the density of CAR on the cell surface and the antigen expression
density. A window of CAR expression density has been described within which the
level of CAR expression does not seem to impact T cell activation [144]. Below T
cell activation is abrogated, however above this window, transduced cells are sus-
ceptible to activation induced cell death (AICD) following engagement to its target
[145]. Seminal work on bi-specific T cell engagers suggested that mutated receptors
with lower affinity to CD3, despite rapid dissociation, efficiently triggered T cell
activation and cytotoxicity [174], and it was suggested that high affinity binding to
CD3 would impede the mediation of serial killing [175]. We therefore rationalized
that there are additional consequences of binding kinetics, which are more signifi-
cant on the cell level, potentially influencing cluster formation with target cells and
T cell effector motility.
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The experimental data presented here support the model of improved func-
tional avidity in T cells expressing CARs with a faster dissociation rate despite a
concomitant lowering of measured affinity for soluble and cell-bound antigen. We
showed that T cells transduced with CAT-CAR demonstrate a greater proliferative
capacity following antigen specific stimulation, an increased capacity to produce
cytokines in response to encounter with antigen, and higher cytotoxic responses in
an antigen specific manner at low effector:target ratios. It should be noted that the
greater capacity of CAT CAR T cells to produce IL-2 in response to activation by
CD19+ targets, acting in concert with signals through the TCR, may have differen-
tial effects on T cell survival and proliferation, and this paracrine effect may also
contribute to the differences observed. In addition, using live cell imaging, we have
demonstrated for the first time that there are significant differences in motility of
high affinity compared to low affinity CAR-T cells, resulting in a greater ability to
interact with targets.
Our data show no difference in exhaustion markers between CAT and FMC63
CAR T cells following a single round of antigenic stimulation but do not address
this in the context of chronic antigen exposure. Loss of effector function during
T cell exhaustion has first been identified during chronic LCMV infection. CD8+
loss of function occurs in a hierarchical manner. Typically, functions such as IL-
2 production, high proliferative capacity and ex vivo killing are lost first. Other
properties, including the ability to produce TNF, are often lost at more intermediate
stages of dysfunction. Severe exhaustion eventually leads to virus-specific cells that
partially or, in some cases, completely lack the ability to produce large amounts of
IFN-γ or to degranulate. The final stage of exhaustion is physical deletion of virus-
specific T cells [170]. Because of induced apoptosis of the target cells, following
irradiation, CAR+ T cells were not chronically stimulated and we were therefore
unable to investigate the effect of persistent antigen encounter. The in vivo studies
discussed in chapter 5 were set up to give further insight into the effect of chronic
antigen stimulation on CAR T cell exhaustion.
Chapter 5
In vivo efficacy
5.1 Introduction
In Chapter 4 we demonstrated that the reduced affinity of CAT CAR, by means
of its quick off rate, paradoxically results in an improved functional avidity with
increased proliferation, cytokine production, and cytotoxic responses in vitro. In-
terestingly, differences in motility of T cells transduced with the different affinity
CARs were identified and the increased motility of CAT CAR T cells was asso-
ciated with an increased number of effector to target interactions and therefore an
increased capacity to serially engage and kill targets.
Previous studies have shown that CD8+ expressing high-affinity TCRs, when
given as adoptive T cell therapy, lose their cytotoxic effector properties, fail to in-
filtrate tumours and are rapidly deleted both in the tumour as well as the periphery
[176–178]. To investigate whether CAR transduced T cells expressing different
affinity receptors might show differences in anti-tumour efficacy, and whether our
findings in vitro would be corroborated in vivo we compared CAT CAR to FMC63
CAR transduced T cells in a xenograft NSG model of established CD19 positive
leukaemia. We hypothesized that, given the previously reported efficacy of FMC63
in vivo [140], in order to clearly delineate differences in functional avidity of CAT
CAR transduced cells, we titrated T cell doses down to a level where T cell doses
are purposefully lowered to only temporarily control leukaemia burden. We utilised
a “stress test” model similar to that developed by Zhao et al. where differences in
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the kinetics of NALM6 tumour control become apparent by lowering CD19 CAR T
cell doses [179].
5.1.1 Aims
• To establish an in vivo model of B-ALL, investigating the tumour cell kinetics
and number of tumour cells required for disease engraftment.
• To perform a dose finding experiment, titrating down the number of CAR T
cells to subject these to an anti-tumour “stress test”.
• To test efficacy and specificity of CAT and FMC63 CAR T-cells in a xenograft
murine model of B-cell leukaemia
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5.2 Results
5.2.1 Tumour cell kinetics and disease engraftment
We set up a xenograft model of NALM6 cells, to study anti-tumour efficacy of
FMC63 and CAT CAR transduced T cells in vivo. These cells were modified to
express firefly luciferase (ffLuc) and GFP [133, 180], allowing non-invasive serial
imaging by bioluminescence (BLI) and flow cytometric analysis. Though Raji tu-
mour cells have been described previously as a model to test CD19 CAR therapy
efficacy [80, 115, 132], because they express several co-stimulatory ligands, such
as CD80 (B7.1) and CD86 (B7.2), which could potentially deliver in vivo prolifera-
tive or anti-apoptotic signals to the infused T cells [101], we chose for the NALM6
model.
Initial tumour and CAR T cell dosing titration experiments were performed,
informed by previously published model designs, that varied from 0.5x106 NALM6
cells in combination with 1−4x105 CAR T cells[179], to 1x106 NALM6 cells com-
bined with either 5x106 [133], or 1x107 CAR T cells [80]. We set up an optimisation
experiment, to determine the optimal number of tumour cells to be given, as dis-
played in the experimental schema in figure 5.1. Different tumour cell doses were
injected i.v. (0.5, 1 & 5x106 NALM6 cells). At day 7 following injection we found
disease engraftment in all three cohorts compared to our negative control (Day 7:
0.5x106 NALM6: 3.7x106 ± 3.4x105; 1x106NALM6: 5.8x106 ± 8.2x105; 5x106
NALM6: 5.6x107± 4.3x106 Mean Ph/sec/cm2/sr ± SEM). Evaluation of tumour
burden by BLI is shown in figure 5.2. Signal localisation was seen in bone marrow,
particularly femurs. Disease levels of the mice that received 5x106 NALM6 cells
were significantly higher than 0.5 and 1 x 106, as assessed by BLI, and we hypothe-
sized this would potentially result in a too aggressive model. Hence, we decided to
choose a lower dose and chose 1x 106 NALM6 cells, on the basis of a 5-fold higher
BLI intensity compared to negative control, confirming disease engraftment in all
animals, but also providing a suitable interval, based on the kinetics of the tumour
growth so that recipient mice could be followed for a meaningful amount of time
before necessitating sacrifice.
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Figure 5.1: Experimental schema of NSG NALM6 tumour model
Mice were injected with 0.5,1&5x106 GFP+Fluc+NALM6 cells. Disease engraftment was assessed at day 3, 7, 9 & 13.
Tumour growth was evaluated using the IVIS imaging system. Photon emission from FLuc+ NALM6 cells was quantified
using Living Image software
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Figure 5.2: In vivo NALM6 tumour cell kinetics and titration
Different tumour cell doses were injected i.v. (0.5, 1 & 5x106 NALM6 cells) to study disease engraftment and determine
optimal tumour cell dose. Each replicate is shown, n=3. Day 7: 0.5x106 NALM6: 3.7x106 ± 3.4x105, 1x106NALM6:
5.8x106±8.2x105, 5x106NALM6: 5.6x107±4.3x106 Mean Ph/sec/cm2/sr ± SEM
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5.2.2 CAR T Cell titration
To recapitulate a situation in which serial engagement of target cells and there-
fore, of killing was advantageous, CAR T cell dose was titrated in order to assess
that with which a temporary control of tumour was achieved, rather than complete
clearance.
Different CAR T cell doses were injected i.v. (1, 5 & 10x106 CAR T cells), 7
days following tumour cells were injected, to study response kinetics. Our aim was
to subject the CAR T cells to a “stress test”. The experimental schema is shown in
figure 5.3. Mice were imaged prior to T-cell treatment to evaluate tumour burden
and were stratified to evenly distribute tumour burden into four groups: mice receiv-
ing 5x106 untransduced T cells, 1, 5 or 10x106 CAR+ T cells. Disease engraftment
was assessed at day -1, 2, 6, 9, 13 & 16 post T cell dose injection. At day 6 fol-
lowing CAR T cell injection we found delayed tumour progression in all 3 CAR
T cell treated cohorts, as compared to 5x106 untransduced T cells, shown in figure
5.4 (Mean Ph/sec/cm2/sr ± SEM : 5x106 Untransduced T cells 3.4x108±1.1x108;
1x106 CAR T cells: 3.7x106± 3.4x105; 5x106CAR T cells: 5.8x106± 8.2x105;
10x106CAR T cells: 5.6x107± 4.3x106). However, it appeared that doses of both
5 and 10x 106 CAR T cells resulted in very rapid disease clearance, where 1x106
did not show clearance but a more heterogeneous image of delayed tumour pro-
gression. Our objective to study differences in functional avidity would require
temporary control of tumour growth and we therefore used a dose of 2-3x106 CAR
T cells in subsequent experiments.
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Figure 5.3: Experimental schema of CAR T cell titration
7 days following tumour injection, mice were injected with 1,5&10x106 CAR+ T cells. Disease engraftment was assessed
at day -1, 2, 6, 9, 13 & 16. Tumour growth was evaluated using the IVIS imaging system. Photon emission from FLuc+
NALM6 cells was quantified using Living Image software
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Figure 5.4: Burden of NALM6 assessed after transfer of varying CAR T cell doses
Different CAR T cell doses were injected i.v. (1, 5 & 10x106 CAR T cells) to study response kinetics. Each replicate is shown,
n=3 mice per group. 5x106 Untransduced T cells 3.4x108± 1.1x108, 1x106 CAR T cells: 3.7x106± 3.4x105, 5x106CAR T
cells: 5.8x106±8.2x105, 10x106CAR T cells: 5.6x107±4.3x106 Ph/sec/cm2/sr ± SEM
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Figure 5.5: Experimental schema of NSG NALM6 xenograft mice model
To assess the ability of CD19 CAR T cells to kill NALM6 tumour in an established tumour model, mice were injected with
1x106 GFP+Fluc+NALM6 cells 24 hours after sublethal irradiation and 7 days prior to T cell injection. Disease engraftment
was assessed at day-1. Cohorts were randomized and recipients with similar tumour burdens were distributed evenly across
the groups prior to CAR T cell injection or non-transduced T cells as negative control. Tumour growth was evaluated using
the IVIS imaging system. Photon emission from FLuc+ NALM6 cells was quantified using Living Image software. Post
termination of the experiment the animals spleen and bone marrow were analyzed by flow cytometry.
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5.2.3 Improved in vivo efficacy of low affinity CD19-CAR+ T
cells against ALL
Having established a tumour and T cell dose which would allow temporary disease
control, we used this model to test the functional avidity of FMC63 and CAT CAR
transduced T cells. The experimental model is shown in figure 5.5. In contrast to the
previous experiments, we sub-lethally irradiated the animals with 2.8 Gy 24 hours
prior to NALM6 tumour cell injection. This was based on previous engraftment
rates of disease in ±65% of the animals. To improve this and ensure engraftment in
all animals, irradiation was used in an optimisation experiment and indeed proved to
increase engraftment levels to 100%. Animals did not show any symptoms related
to the irradiation.
Mice were imaged prior to T cell treatment to evaluate tumour burden and were
stratified to evenly distribute tumour burden into four groups. One group was treated
with untransduced T cells and served as control for xenogeneic T cell responses.
The experimental arms received 2.5x106 CAR transduced T cells expressing either
FMC63 CAR or CAT CAR.
Results of two independent experiments with comparable results are shown.
Both CAT and FMC63 CAR transduced T cell products had a comparable distribu-
tion of CD4 and CD8 T cells prior to infusion as shown in figure 5.6. CAR expres-
sion levels were determined in both experiments and as in the in vitro experiments,
where there were significant differences in transduction efficiency, non-transduced
T cells were added to normalise the CAR+ percentage in each groups.
All animals were followed for tumour burden by BLI (Fig. 5.7). Control
mice receiving untransduced T cells showed rapid, disseminated tumour infiltra-
tion. Both the FMC63 and CAT cohorts were able to delay tumour growth, but CAT
transduced T cells were more effective at inhibiting tumour growth compared to
FMC63 expressing T cells from the same donor. On day 12 post T cell injection,
substantial differences were seen in tumour burden as assessed by IVIS(Fig. 5.8
CAT CAR: 1.1x108±9.3x107, FMC63 CAR 3.2x109±7.7x108, Mean ph/sec/cm2,
n=18, p<0.001) .
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Figure 5.6: CD4/CD8 distribution of FMC63 and CAT CAR+ T cells prior to infusion
FMC63 CAR+ and CAT CAR+ T cells were evaluated for CD4/CD8 ratio by flow cytometry. FACS plots show distribution
of the T cell product 24 hours prior to infusion.
To test if our in vitro findings of a greater proliferative capacity of CAT CAR
transduced T cells correlated with increased proliferation of CAR+ T cells in vivo,
we directly quantified the absolute number of FMC63 and CAT CAR transduced
cells. Two weeks after infusion of CAR T cells peripheral blood samples were
analysed, revealing a significantly greater absolute number of CAT CAR T cells
in the circulation (Mean±SEM CAT 18743 ± 3127, FMC63 2843 ± 818.7CAR T
cells/ml, n=9, p<0.001, Fig. 5.9c). This was associated with a lower number of
NALM6 cells in the circulation of recipients of CAT CAR T cells (Mean±SEM
13.19 ± 5.494 CAT CAR, 594.5 ± 157.9 FMC63 CAR NALM6 cells/ml, n=9,
p<0.01, Fig.5.10a). Similarly, FACS analysis of bone marrow after sacrifice, re-
vealed a greater absolute number of CAR T cells in the CAT cohort compared
to FMC63 (MeanSE cells/ml: 5.1x104 ± 1.2x104 CAT CAR; 2.0x104 ± 4.6x103
FMC63 CAR, n=9, p<0.05, Fig. 5.9a) and a higher number of NALM6 cells in
recipients of FMC63 CAR T cells (Mean: 3x102 NALM6 cells/ml in CAT cohort,
2.8x105 NALM6/ml in FMC63 Cohort, n=9, p<0.001, Fig. 5.10b).
CAT CAR T cells accumulated greater at the disease site, as well as in the pe-
ripheral secondary lymphoid compartments, however a skewed distribution of CAR
T cells into other organs can not be excluded, potentially explaining a difference
in absolute number between FMC63 and CAT CAR transduced T cells, as these
were not formally assessed. However such trafficking would be not be expected
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given the comparable frequency of CAR T cells within distinct memory compart-
ments (Mean % ± SEM; FMC63 CAR T cells: Naive 35.1±3.1, CM 8.4±1.9, EM
28.8±3.3, TEMRA 27.7±3.0, CAT CAR T cells: Naive 29.9±2.8, CM6.3±0.5,
EM 36.7±3.2, TEMRA 27.1±0.9), determined by CCR7 and CD45RA expression
(Fig. 5.11b), as well as their CD4/CD8 distribution (Fig. 5.11c, % CD8+ ± SEM
FMC63 43.6±1.0, CAT 41.7±3.9, NT 33.7±0.4).
The greater production of IL-2 in vitro as shown in section 4.2.4.1 may con-
tribute to the greater proliferative capacity of CAT CAR transduced T cells. Similar
to our findings in vitro, intracellular staining of Th1 like cytokines revealed that
CAT CAR T cells at the tumour site show a greater ability to express TNF-α and
again a trend towards greater expression of IL-2, 14 days following transfer to tu-
mour bearing hosts (Fig. 5.12). When the expression of activation and exhaustion
markers was investigated on CAR transduced T cells from the bone marrow, 15
days after infusion, we found comparable levels of expression of TIM3, LAG3 and
PD1 in mice receiving FMC63 CAR transduced T cells as those treated with CAT
CAR T cells(Fig. 5.13, MFI ± SEM of CAR transduced T cells in bone marrow
15 days following infusion. TIM3: FMC63 541.4 ± 121.7, CAT 512.8 ± 71.14,
LAG3: FMC63 186.6 ± 25.95, CAT 203.2 ± 19.15, PD1: FMC63 86.04 ± 22.3,
CAT 73.52 ± 7.703).
Several studies have suggested that the expansion and differentiation program
is imprinted shortly after antigenic stimulation [181]. Virus-specific CD8 T cells
generated during chronic, but not acute, LCMV infection expressed low levels of
CD127 and CD122, the receptors for the homeostatic cytokines IL-7 and IL-15, re-
spectively [182]. IL-7 is involved in maintaining memory populations and IL-7Rα
signalling has an important function in T cell survival by increasing the expression
of anti-apoptotic molecules (Bcl-2 and Bcl-XL)[183]. Van Leeuwen et al. describe
that in chronic infections IL-7Rα+ T cells express higher levels of Bcl-2 and show
a superior recall response and enhanced proliferation in response to homeostatic
signals [181]. Interestingly when we investigated IL-7Rα expression (CD127) on
CAR transduced T cells, we found a significantly greater proportion of IL-7Rα+
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CAT CAR transduced T cells (Fig. 5.14, % CD127+ CAR+ T cells in BM: FMC63
22.96 ± 1.839, CAT 34.08 ± 1.944), as well as significantly higher expression lev-
els (Fig. 5.14, MFI CD127 CAR+ T cells in BM FMC63 201.7 ± 13.7, CAT 299.8
± 11.9) compared to FMC63 CAR T cells. This directly correlated with an upreg-
ulation of the anti-apoptotic molecule Bcl-2, akin to results previously reported in
chronic infections [183]. Over-expression of Bcl-2 inhibits the intrinsic apoptotic
pathway, critical in regulating T cell survival, and is actively regulated in peripheral
T cells, being upregulated in naive cells and memory cells and downregulated in
the effector phase [184]. Intracytoplasmic flow cytometric analysis on the BM of
treated mice (Fig. 5.15) showed both higher levels (MFI Bcl2 CAR+ T cells in BM:
FMC63 124± 26.27, CAT 337.6± 35.4), and a greater proportion of Bcl2+ CAR T
cells (Fig. 5.15, % Bcl2+ CAR+ T cells in BM: FMC63 10.24 ± 2.667, CAT 34.66
± 3.345) in mice treated with CAT CAR T cells than FMC63 CAR T cells.
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Figure 5.8: CAT CAR+ T cells show enhanced disease inhibition after transfer to tumour
bearing hosts
Mice were injected with 1x106 GFP+Fluc+NALM6 cells 24 hours after sublethal irradiation and 7 days prior to T cell injec-
tion. Disease engraftment was assessed at day-1. Cohorts were randomized and recipients with similar tumour burdens were
distributed evenly across the groups prior to CAR T cell injection or non-transduced T cells as negative control. Tumour
growth was evaluated using the IVIS imaging system. The graph shows the kinetics of tumour growth. Photon emission from
FLuc+ tumor cells was quantified and measured as maximum photon/sec/cm2/steradian (p/s/cm2/sr).Lines represent cumu-
lative results of light emission values ± SEM bioluminescence signal determined in 2 separate experiments,n=18, Student
t-test, **p<0.001, *** p<0.001.
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(a)
(b)
(c)
Figure 5.9: CAT CAR+ T cells accumulate in greater number in vivo
After termination of the experiment 16days following infusion of CAR T cells, bone marrow, spleen and peripheral blood
were investigated for presence of CAR T cells. Mean number ± SEM: (A) Bone marrow: CAT 3.4x104±8.1x103, FMC63
1.3x104±3.1x103 n=18, P<0.05 (B) Spleen: CAT 3.2x105±6.2x104, FMC 7.3x104±3.0x104, n=9, p<0.01 (C) peripheral
blood: CAT 1.9x104±3.1x103, FMC63 2.8x103±8.2x102, n=9, p<0.001. Statistical comparisons were made using a two-
sided student t-test.
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(a)
(b)
Figure 5.10: NALM6 cell absolute numbers are reduced in cohort that received CAT CAR
transduced T cells compared to FMC63 and non-transduced T cells
Absolute numbers of NALM6 + cells were assessed in (A) peripheral blood and (B) bone marrow, n=18, statistical analysis
was done by the use of a two-sided student t test; **, P<0.01, ***, P<0.001
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Figure 5.11: The distribution of CAR T cells in the bone marrow between CD4 and CD8 as
well as memory compartments was not significantly different 15 days after transfer to tumour
bearing hosts
(A) Representative FACS-plot of memory compartments, identified by CD45RA and CCR7 expression, gated on CAR+ T
cells in bone marrow by flow cytometry, on day 15 post T cell injection. (B) Mean % ± SEM; FMC63 CAR T cells: Naive
35.1±3.1, CM 8.4±1.9, EM 28.8±3.3, TEMRA 27.7±3.0, CAT CAR T cells: Naive 29.9±2.8, CM6.3±0.5, EM 36.7±3.2,
TEMRA 27.1±0.9), determined by CCR7 and CD45RA expression (C)% CD8+ ± SEM FMC63 43.6±1.0, CAT 41.7±3.9,
NT 33.7±0.4
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(a)
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Figure 5.12: CAT CAR T cells at the tumour site showed a greater ability to express TNF-
αafter transfer to tumour bearing hosts
Percentage of cytokine-producing CAR T cells in bone marrow was determined by flow cytometry after gating on CAR+ T
cells. Data, mean percent producing ± SD, n=4; two-sided student t test; *P < 0.05
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Figure 5.13: Activation/Exhaustion marker expression levels of CAR+ cells in bone marrow
Mean fluorescence intensity of the expression levels activation/exhaustion markers LAG3, PD-1 and TIM3 on CAR T cells
in the bone marrow was assessed by flow cytometry 15 days following infusion. MFI ± SEM TIM3: FMC63 541.4 ± 121.7,
CAT 512.8 ± 71.14, LAG3: FMC63 186.6 ± 25.95, CAT 203.2 ± 19.15, PD1: FMC63 86.04 ± 22.3, CAT 73.52 ± 7.703.
Data, mean ± SD, n=9
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Figure 5.14: A greater proportion of CAT CAR+ cells in the bone marrow was CD127 positive
and showed greater levels of CD127 expression 15 days following infusion
CD127 positive cells in bone marrow and expression levels were determined by flow cytometry after gating on CAR+ T cells.
(A) Proportion of CD127 positive cells (B) MFI of CD127 expression levels (C) Representative FACS plots. Data, mean ±
SD, n=5 in FMC63 and n=9 in CAT; *, P < 0.05, ***, P < 0.0001, two-sided student t test.
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Figure 5.15: A greater proportion of CAT CAR+ cells in the bone marrow was Bcl2 positive
and showed greater levels of expression 15 days following infusion
Bcl2 positive cells in bone marrow and expression levels were determined by flow cytometry after gating on permeabilized
CAR+ T cells. (A) Proportion of Bcl-2 positive cells (B) MFI of Bcl-2 expression levels (C) Representative FACS plots.
Data, mean ± SD, n=5 in FMC63 and n=9 in CAT;**P < 0.01, ***,P < 0.001, two-sided student t test.
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5.3 Discussion
Whilst both CAT and FMC63 CAR transduced T cells were able to mediate effective
dose-responsive anti-tumour responses in a xenogeneic model, when more stringent
conditions were used to favour the tumour, CAT CAR transduced T cells showed
enhanced disease clearance, TNF-α secretion and accumulation both in the bone
marrow and the periphery. These data reflect our in vitro findings that CAT CAR
T cells are able to proliferate more and show enhanced Th1 cytokine secretion in
response to CD19+ targets.
It has been previously reported that increased TCR-pMHC interactions in vivo
result in decreased proliferation, cytokine production and memory formation [185]
and intermediate affinity T cells are suggested to better control tumour growth than
their high affinity counterparts [178, 185]. In addition, it has been demonstrated that
chronic viral infection in mice can convert an otherwise effective antiviral CD8+ T
cell response to an ineffective or inefficient response. This conversion is associated
with a step-wise impairment, or exhaustion, in the effector functions and prolifera-
tive capacity of responding antigen-specific CD8+ T cells[186]. We observed sig-
nificantly higher levels of IL-7Rα and Bcl-2 expression in CAT CAR transduced T
cells responding to persistent tumour burden compared to FMC63 CAR transduced
T cells. Overexpression of these markers has shown significant impact on prolifer-
ation and protection from activation induced cell death (AICD) [187] and previous
studies indicated that the generation of memory CD8+ T cells critically depends on
the function of Bcl-2 during the contraction phase of a T cell response [188]. The
upregulation of IL-7Rα and Bcl-2 in CAT-CAR transduced T cells responding to
persistent tumour burden compared to FMC63 CAR transduced T cells may reflect
differences in downstream CAR signalling and changes in intracellular signalling,
thus it is possible that the greater accumulation of CAT CAR T cells was related to
a reduction in apoptosis and greater survival, though increased proliferation of CAT
CAR T cell or trafficking of FMC63 out of the secondary lymphoid compartments
can not be excluded.
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Although the xenograft NSG model is commonly used as a model to study
efficacy of CAR transduced T cells, due to their receptivity to human cells, this
model is also limited by the development of xenogeneic (xeno-)GvHD. We observed
symptoms related to xeno-GvHD (piloerection, hunched posture, weight loss) two
weeks following T cell injection, limiting us in the duration that we could study our
different cohorts. The increased proliferative response of CAT CAR transduced T
cells and its apparent improved fitness justified further studies in the persistence of
these CAR T cells and their ability to clear disease when being re-challenged with
tumour cells.
In addition, because this is an immunocompromised model, we are unable to
study the interaction of CAR T cells with other components of the immune system,
such as macrophages, playing a pivotal role in toxicities caused by CAR T cells such
as CRS [159, 189, 190]. The pathological mechanisms are not yet understood, but
T cell-mediated therapies lead to proinflammatory cytokine production, which may
trigger CRS. Whether a low affinity CAR T cell interaction might also influence the
interaction with bystander immune cells is yet unidentified.
Chapter 6
General discussion and future work
6.1 CD19 binding kinetics
CAR T cell therapy holds great promise for the therapy of cancer, but the opti-
mal design of CARs has yet to be established. The overarching aim of this project
was to investigate the impact of scFv affinity, and in particular the off rate, on CAR-
mediated T-cell function. We generated 2 CARs that are identical in backbone other
than their CD19-targeting domain. The data presented here show that the affinity
of the different anti CD19 scFvs, ranging from KD 0.9nM to 116nM, is signifi-
cantly higher than the wild type TCR affinity, ranging from KD 1µM to 50µM[31].
However, the influences of differences in on- and off-rates underlying the binding
kinetics of CD19 CARs on downstream CAR T cell responses have never been di-
rectly compared. We sought to explore this effect specifically and constructed a
novel anti-CD19 CAR derived from the CAT hybridoma.
SPR analysis by Biacore revealed a distinct kinetic profile for this new scFv
CAT demonstrating a greater off-rate (kd FMC63 5.5x10−4 and kd CAT 7.07x10−2),
whilst maintaining an on-rate nearly identical to FMC63 (ka FMC63 6.24x105 and
ka CAT 6.09x105), employed in published clinical studies [78, 85]. The differences
in affinity were confirmed against naturally expressing Raji cells by Scatchard anal-
ysis. Clearly, neither of these assays fully recapitulate the binding of a membrane
bound CAR on a T cell to CD19 on the target cell and both eliminate cell adhe-
sion and binding of other ligand-receptor pairs which may affect functional avidity
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but nonetheless these are currently the best assays available for addressing this is-
sue and provide valuable insights into the binding of a soluble scFv-Fc to soluble
or naturally expressed antigen respectively. The affinity as compared to functional
avidity describes the thermodynamic parameter, the KD value, defined by a simple
equilibrium binding reaction. The functional avidity describes the ability of a CAR
T cell to respond to the stimulation provided by tumour associated antigens and is
influenced by CAR T cell affinity, CAR expression levels and the location of the
recognized epitope on the antigen [191].
To investigate the epitope binding specificity of CAT scFv compared to FMC63
we constructed the full length peptide and three variants with increasing truncation
of CD19 (∆ex2, ∆ex2-3, ∆ex2-3-4). Although we did not perform formal epitope
mapping studies, we were able to confirm binding of both FMC63 and CAT scFv
to the first Ig loop in exon 2. This suggests that differences in synapse width were
unlikely to contribute to differences in CAR T cell responses, however this cannot
be completely excluded. We and others have observed that the the frameshift muta-
tions clustered in the nonconstitutive exon 2 eliminate full-length CD19, but allow
expression of the ∆ex2 isoform in the cytosol [95]. The cytosolic localisation of ∆
ex2 CD19 precludes it being targeted by novel CD19 CARs that target the second Ig
loop, as a way to prevent escape, because of their restriction to binding cell surface
molecules.
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6.2 Delineating the impact of binding-domain affin-
ity on CAR T-cell function
TCR affinity influences the sensitivity and polyfunctionality of T cells. In target-
ing of antigens for therapeutic purposes, it was previously assumed that the higher
affinity of the interaction, the greater the associated cellular immune response. This
was based on observations such as TCRs specific for pathogens (non-self) having a
higher affinity and KD values that are generally about 10-fold lower when compared
to TCRs specific for TAAs (as self-antigens) [21]. Taking this to its natural conclu-
sion, TCRs were then affinity matured with the aim of enhancing downstream T
cell responses. This was beneficial in some cases, supported by observations that
a high-affinity MART-1/HLA-A2 TCR mediated improved objective response rates
compared to a lower affinity TCR, and the observation that an affinity-enhanced
NY-ESO1 TCR mediated significant clinical responses [21]. However, it was also
shown that T cell function could not be further improved raising TCR affinity above
the natural range (KD < 1µM) [150] and by doing so the increased affinity led to
loss of antigen sensitivity, specificity and cross-reactivity [20, 22, 192], resulting in
treatment-related toxicity including severe but treatable inflammation of skin, eyes,
ears (MART-1/HLA-A2; gp100/HLA-A2), and colon (CEA/HLA-A2) [21].
There are different theories as to what kinetic properties underlie the best T
cell activation and signalling. The kinetic proofreading model suggests that off
rates should be sufficiently slow to allow a threshold for immunoreceptor-based
signalling to be surpassed and full T cell activation to occur. A study with the
human NY-ESO-TCR showed that an increase in t1/2 from 2.2 seconds for the wild-
type TCR to 19 seconds for an affinity-matured TCR improved the ability of TCR
transduced CD8+ T cells to recognize NY-ESO-expressing tumour cells, and this
improvement was not seen with an affinity-matured TCR with a t1/2 of 41 sec-
onds [193]. This was supported by findings that optimal TCR peptide sensitivity
is achieved with dissociation half time (t1/2) of 9.3 seconds, and that when t1/2 was
increased to 348, 1320, and 3120 seconds this resulted in a progressive loss of pep-
tide sensitivity and even impaired T cell function. [31, 33]. The half-lives of the
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interactions between a TCR and foreign-pMHC agonists are characteristically 2-10
seconds [14]. At low antigen density, which is most physiologically relevant, suf-
ficient T cell activation requires serial triggering. Tumour-associated peptide anti-
gens are generally present at fewer than 50 copies per cell [22]. It is possible that
TCR-pMHC interactions that have excessively long half-lives could impair the se-
rial engagement of TCRs by low-density cognate pMHC on the target-cell surface,
which would prevent T cell activation. However, when one considers the setting of
increased antigen density, the abundance of antigen leads to simultaneous binding
of sufficient pMHC complexes to TCRs, diminishing the need for serial triggering
and the inhibition caused by the longer t1/2 is lessened. The potential inhibition of
T cell functions as a result of a long t1/2 may well underlie the absence of a mecha-
nism for affinity maturation of TCRs during T cell responses to pathogens, which in
contrast to adaptive antibody-mediated immune responses is associated with lower
affinities.
Irving et al. observed that there were maximal T cell responses at lower affini-
ties, with a plateau of functional output between KD 1 µM and 5 µM [23]. Reducing
the TCR affinity further however, has demonstrated to affect different parameters of
T cell activation such as the phosphorylation of CD3ζ, the activation of the MAP
kinase pathways and the ability to recruit cytotoxic granules [16, 24, 25]. Thus,
there appears to be a defined window of half-life of TCR-ligand interactions and
number of TCRs engaged. While very short half-lives avert productive TCR trig-
gering, half-lives exceeding the optimum interaction time decrease the efficiency of
TCR serial engagement.
Studying CAR T cell functional efficacy, Turatti et al. show that when CAR
and antigen levels are both high, the threshold for complete T cell activation is
readily met, regardless of CAR affinity, due to high numbers of simultaneous CAR-
antigen binding events. However, when both the expression levels of CAR and
antigen are low, the function of the CAR appears to be determined by the affinity
of the CAR: low affinity CARs with high off-rates remain functional, whereas high
affinity CARs appear impaired [146]. Lehner et al. report that CAR T cells require
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at least a 100-fold higher target antigen densities than natural TCRs because of the
higher affinity of the CAR for antigen, resulting in a longer half life of interaction,
and an inability to support efficient serial triggering as a result, although this study
did not test CARs with quick dissociation rates [194]. In T cells transduced with
affinity matured TCR (engineered to enhance affinity for pMHC), this was also
described. To trigger T cell responses in these transduced T cells, again a 100-
fold higher pMHC densities was required compared to wild-type TCR [31]. Thus
CAR affinity may be a relevant determinant of CAR T cell activation in response to
CD19, were primary cell targets typically express 3000 CD19 molecules per cell.
A study by Oren et al. in which they compared TCR-like Abs, targeting HLA-
A2-WT1Db126 complexes, as a binding moiety in CAR T cell therapy to a native
low affinity αβ-TCR chain, again revealed that above a threshold of TCR-pMHC
affinity (KD < 5µM) T cell function could not be further enhanced. In addition
work performed on NYESO-1 αβ-TCR CARs defined the upper affinity limit of
TCR for specific Ag recognition as 280-450 nM [150].
Chmielewski et al. investigated the effect of receptor binding affinity on CAR
effectiveness, by the use of a library of affinity matured anti-ERB2 scFvs, with
affinities ranging broadly from KD 3x10−7 to 1.5x10−11 M. Importantly these scFvs
had identical epitope specifity and the CAR backbone was otherwise identical. They
showed that there is a threshold affinity beyond which no improvement in T cell
function is achieved, defined as ”the affinity ceiling” [147]. The likely explanation
for the plateau effect is that the avidity of the CAR needed for maximal T-cell acti-
vation is a function of the number and density of the expressed receptors as well as
their affinity. In their model the CAR-mediated cytotoxic effect on target cells and
the release of IFN-γ and IL-2 did not increase above an affinity of KD < 1x10−8 M.
This was supported by a study conducted by Haso et al. in which CARs containing
three distinct binding domains targeting CD22 were compared. They showed that
CAR lytic activity did not vary based on scFv affinity (comparing 2 murine CD22
scFvs with respective KD values of 5.8 nM and 2.3 nM, and a humanized scFv with
a KD value of 20nM), but rather on the epitope specificity, with CARs targeting a
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proximal CD22 epitope demonstrating superior antileukaemic activity [148]. How-
ever, CARs specific for ROR1 with varying affinity of scFv were also investigated
to determine the impact of affinity on CAR-mediated T-cell function and higher
affinity was associated with increased T cell function in this study as measured by
cytokine production, proliferation and in vivo efficacy. Biacore assessment of the
scFv with the highest affinity revealed a balanced distribution of both a high kon
and a low koff contributing to the low KD value [128]. Discrepancies between the
previous studies can be accounted for by methodological differences. In the ROR1
study CARs with different backbones were compared with respect to their efficacy
in redirecting T cells. Also, the two binding domains compared in this study had
different epitope specificity.
Caruso et al. compared two scFvs (derived from mAbs Nimotuzumab and Ce-
tuximab) of different affinity targeting EGFR. Nimotuzumab had a nearly 60- fold
reduced on-rate of binding compared to Cetuximab and a resulting reduced affin-
ity of binding to EGFR (SPR Biacore Nimotuzumab: KD = 2.1x108 mol/L, kon =
5.2x104, koff = 1.1x103; Cetuximab: KD = 1.8x109, kon = 3.1x106, koff = 5.8x103)
[195]. In Caruso’s study the Nimotuzumab CAR with reduced affinity was unable
to recognize EGFR expressed at reduced levels, exhibiting a gradient of T-cell ac-
tivation that directly correlated with density of expression of EGFR [151]. These
results were in contrast to our findings where it appeared that CAT CAR transduced
cells showed improved functional avidity against the SUPT1CD19LO cell line in
a 24hour cytotoxicity assay compared to FMC63 transduced T cells. It is possible
that the reduced affinity of Nimotuzumab CAR transduced T cell as a result of a
much slower on-rate may explain these differences in outcome. In fact, the higher
affinity Cetuximab has a quicker off-rate and when one calculates the interaction
half-time Cetuximab has a t1/2 of 119 minutes, compared to a t1/2 of Nimotuzumab
of 149 minutes. This in combination with antigen expression levels of approxi-
mately 30,000 copies of EGFR/cell on their lowest expressing cell line, which is
significantly higher than the 140 copies/cell on SupT1CD19LO, suggest that these
results do not reflect differences in serial triggering but instead show reduced acti-
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vation of Nimotuzumab CAR T cells as a result of a reduced on-rate. Site-directed
mutagenesis excluded differences in epitope specificity as a potential contributor,
showing that the Nimotuzumab epitope strongly overlaps with the Cetuximab bind-
ing site [195].
6.2.1 Lower CAR affinity in the context of a faster off-rate re-
sults in increased antigen-specific responses and is associ-
ated with enhanced proliferation
Our comparison shows that higher affinity scFvs do not translate into greater pro-
liferation or cytotoxicity. In fact the opposite appears to be the case. The scFvs of
which the CD19 CARs were derived differed mostly in off-rate as opposed to on-
rate and so greater affinity was caused by prolonged association with the antigen.
Evidence supports both Kd and koff as determinants of T-cell function [196]. By the
use of in vitro pre-clinical models we were able to demonstrate that CAT-CAR+ T
cells show increased proliferation following antigenic stimulation in cytokine-free
conditions, and increased capacity to produce TNFα and perhaps IL-2 in response
to encounter with antigen in comparison to T cells from the same donors expressing
FMC63 CAR. These findings were replicated in our in vivo model system. CAT
CAR transduced T cells showed enhanced cytotoxicity than FMC63 in cell lines
with high antigen density. Against targets with low antigen density our data suggest
that CAT CAR T cells show a trend towards an improved ability to kill compared
with FMC63 at low E:T ratios. The reduced affinity of CAT might therefore be
mitigated by its short dissociation rate, favouring serial triggering as well as serial
killing. Using live cell imaging, we observed a significantly greater number of ef-
fector:target interactions with CAT CAR over 20 hours. In addition, it appeared that
CAT CAR T cells accumulated several contemporaneous interactions with targets
cells. Interestingly, the duration of these interactions were not significantly reduced
compared to FMC63 transduced T cell, though marked differences were found in
the motility of CAT transduced T cells, showing greater displacement over time.
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Thus, the lower affinity of CAT CAR-CD19 interaction may facilitate more rapid
interaction with multiple CD19+ targets.
It has been hypothesized that there is a potential upper limit to increased re-
sponsiveness to high affinity interactions, otherwise leading to attenuation of intra-
cellular signalling and expansion [197]. An interesting systematic analysis of T cell
responses by Omer Dushek’s lab of the high-affinity engineered c58c61 TCR that
binds the NY-ESO-1 cancer antigen, to measure primary human T-cell activation in
response to a 1 million-fold variation in pMHC affinity and dose, concluded that
there is a bell-shaped response with reduced cytokine production at high peptide-
MHC concentrations, and the peak amplitude of the dose-response response curve
is independent of the affinity of the interaction. However, an intermediate affinity
interaction produces the largest response at low doses of pMHC [36]. The interme-
diate affinity ligand employed had very similar kinetic characteristics to the CAT
scFv. Although a bell-shaped dose-response can be a result of AICD, they show
that this was unlikely to be the case in their experiment. They found that the dose-
response for cytokine production appeared bell-shaped at all times with continued
cytokine production to the right of the peak. Moreover, direct detection of apopto-
sis by annexin V binding revealed a maximum of only 10%, which is insufficient
to explain the observed reduction in cytokine production. These observations sug-
gested a reduced rate of cytokine production per cell at high pMHC doses, which
they confirmed using single-cell cytokine production.
Using model identification algorithms they propose a model in which the TCR-
pMHC complex directly inhibits a node P and indirectly activates P (by activating
Y, which itself is able to activate P). The model can produce inhibition at high
pMHC concentrations if the activatory pathway (through Y) saturates, allowing in-
hibition to dominate at the highest pMHC concentrations. This model however,
would result in a bell-shaped dose-response for all pMHC ligands independent of
their affinity. They then introduce kinetic proofreading, by means that the pMHC
ligand does not trigger signalling immediately upon binding TCR but instead must
remain bound until it becomes signalling-competent (denoted as C1). This delay
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means that low-affinity pMHCs (with faster koff) induce a lower maximal concen-
tration of C1. If this is below the level at which Y saturates then inhibition at high
pMHC concentrations will not be observed with low-affinity pMHC. This model,
however, is also rejected because it predicts that the highest-affinity ligand will pro-
duce the largest response left of the peak in contrast to experimental observations.
They then introduce limited signalling into kinetic proofreading. In this model, ac-
tivated TCR-pMHC complexes (C1) signal for a limited period before converting
to a nonsignalling state (C2), thereby introducing a penalty for pMHCs that remain
bound for long periods of time. This model is now able to explain all key features
and is accepted as a plausible signalling model for T-cell activation [36] and may
be an explanation for the different functional output of CAT CAR transduced T
cells compared to FMC63. An experiment in which we would compare CAR T
cell functionality targeting a full range of SupT1 cells expressing CD19 antigen at
varying levels, would give further insight. We would expect to see a bell-shape dose
response curve in FMC63 CAR T cells and potentially CAT CAR T cells, although
we hypothesize that the curve of CAT CAR transduced T cells may look signifi-
cantly different, as the activation pathway might never be saturated, compared to
the inhibitory pathway by means of its quick dissociation.
In resting T cells the TCR/CD3 complex is stable and gets rapidly recy-
cled after internalization [168, 198]. Internalization is a parameter for TCR se-
rial triggering and is characteristic of productive TCR engagement by agonist lig-
ands [34]. Following ligation of the TCR the downregulation is mediated by
intracellular retention, preventing recycling, and degradation by lysosomes and
proteasomes[145, 198]. CAR downregulation has been described previously[194].
In our study, antigen-induced CAR downregulation was only observed for CAT-
CAR transduced cells. T cells expressing FMC63 did not significantly downregu-
late their CAR expression. These results are in agreement with our in vitro findings,
suggesting increased activation in CAT possibly resulting by serial triggering. Sus-
tained CAR signalling has been associated with AICD, suggesting that CAR down-
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regulation might be beneficial to reduce the ongoing signalling in the presence of
large antigen burdens.
The TCR signalling machinery is pivotal in regulating the response of a T cell
following antigen exposure [14]. Interactions of the TCR with pMHC complexes
induce full calcium signalling, crucial for T cell activation, requiring multiple in-
tracellular reactions that are completed within 6-7 seconds following TCR ligation
[14], as discussed in section 1.2.2. Signal initiation and propagation are driven by
rapid biochemical reactions that induce or amplify the physical connectivity and
catalytic activity of signalling components. Regulatory mechanisms that oppose
these events allow the signals to be controlled or stopped and secure appropriate
responses. Following TCR engagement, phosphorylation and dephosphorylation
reactions allow signalling circuits to rapidly establish a new steady-state [14]. As
shown in figure 6.1 t1/2 of TCR-MHC interaction impacts the T cell functional out-
come. A long t1/2 might induce a state of tonic signalling, negatively affecting
functional avidity by means of preventing cells from recovering to a more quiescent
state, which in turn would prevent further productive T cell activation and induce
AICD. We hypothesize that FMC63 CAR T cells were potentially unable to re-
engage with new target cells because of tonic signalling in the presence of antigen-
bearing cells. CAT CAR T cells showed a greater ability to repeatedly productively
engage targets, however whether longer t1/2 of CAR binding results in impaired
ability of CAR T cells to serially engage multiple targets, by means of preventing T
cell recovery and/or inducing AICD has not yet been studied. The relation between
t1/2, CAR T cell recovery and CAR T cell motility warrants further studies, as will
further be discussed in more detail.
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Figure 6.1: Optimal window of TCR-pMHC interaction time
Adapted from [28]
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6.2.2 Low affinity CD19-CAR+ T cells show improved in vivo
anti-leukaemic efficacy
Although functional effector T cells can transiently express inhibitory receptors dur-
ing activation, prolonged and/or high expression of multiple inhibitory/activation
receptors is a key feature of the exhaustion of CD8+ and CD4+ T cells [170]. Loss
of effector function during T cell exhaustion has first been identified during chronic
LCMV infection. CD8+ loss of function occurs in a hierarchical manner [170].
The expression of PD-1 and TIM3 on FMC63 and CAT CAR transduced T cells
was analysed 7 days after the start of a 1:1 co-culture with irradiated Raji cells,
and showed no significant difference between CAT and FMC63 CAR transduced T
cells. Because of induced apoptosis of the target cells, following irradiation, CAR+
T cells were not chronically stimulated and we were therefore unable to investigate
the effect of persistent antigen encounter. However, it has been shown that early in-
teractions with target cells dictate the eventual fate of CD8+ cells and their memory
recall capacity [199]. Long et al. showed that early T cell exhaustion is a primary
factor limiting the antitumour efficacy of CAR-expressing T cells and that CAR
structure has a central role in predisposing CAR T cells to chronic activation and
exhaustion, affecting 3 pathways: i) response to hypoxia, ii) cellular metabolism
and iii) negative regulation of apoptosis, however they did not investigate the im-
pact of CAR T cell affinity in this study.
The in vivo studies discussed in chapter 5 investigated the effect of chronic
antigen stimulation on CAR T cell exhaustion. We hypothesized that by subject-
ing CAR transduced T cells to a “stress test”, letting the tumour cells fully engraft
prior to infusion of suboptimal T cell doses, we would identify differences that may
not have become clear in our in vitro studies, such as T cell exhaustion resulting
in reduced anti-leukaemic efficacy. It has been shown that increased TCR-pMHC
interactions in vivo result in decreased proliferation, cytokine production and mem-
ory formation. Corse et al. showed that optimal in vivo responses occur to ligands
with intermediate TCR/pMHC half-lives[185]. In fact they observed a diminished
response to the ligand exhibiting the longest half-life, associated with attenuation of
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intracellular signalling, expansion and T cell function. Various groups have shown
that when CD8+ expressing high-affinity TCRs, are given as adoptive T cell ther-
apy, they lose their cytotoxic effector properties, fail to infiltrate tumours and are
rapidly deleted both in the tumour as well as the periphery [176–178]. When anti-
gen is not cleared functional antigen-specific T cells are eventually lost. Both early
fate decisions, such as survival and memory precursor formation, and late fitness
of antigen-specific CD8+ populations can be compromised [199]. The level of in-
dividual peptides presented in vivo is an important determinant of both functional
exhaustion and physical deletion and a high level of persistent epitope presentation
may lead to deletion, while persistence of lower-level TAAs stimulation may result
in functional impairment, as a result of strong coinhibitory signals and progressive
loss of effector function[200].
Our results from two independent experiments indicate that greater disease
control was achieved by lower affinity CAR T cells in vivo. Both the FMC63 and
CAT cohort were able to delay tumour growth but CAT transduced T cells were
more effective at inhibiting tumour growth compared to FMC63 expressing T cells
from the same donors and on day 12 post T cell injection substantial differences
were seen in tumour burden (Fig. 5.8, BLI CAT CAR: 1.1x108±9.3x107, FMC63
CAR 3.2x109±7.7x108 Mean ph/sec/cm2). CAT CAR T cells accumulated greater
at the disease site, as well as in periphery (blood and spleen). This may result
from their greater proliferative capacity or protection from activation induced cell
death (AICD) or both. However we cannot exclude distribution of CAR T cells into
organs other than secondary lymphoid compartments, as we did not investigate any
further organs, which could potentially explain the difference in absolute number
between FMC63 and CAT CAR transduced T cells.
Early, functional T cells in acute infections temporarily express high levels of
inhibitory receptors such as PD-1, LAG-3 and TIM3 [182]. The expression of these
inhibitory receptors was not significantly different in the CAR transduced T cells.
These phenotypic characterisations were first described in persisting LCMV infec-
tions. Subsequently, they were also found in HIV and hepatitis C virus infections
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and the presence of this chronic phenotype is generally considered a sign of a deteri-
orating T cell response [201]. A potential explanation for the lack of up-regulation
of these parameters in FMC63 transduced T cells might be that the earliest time-
point chosen to study these phenotypic characterisations was two weeks following
injection, and therefore exhausted T cells might already have undergone AICD.
Unpublished results from our group revealed significantly lower levels of PD-1 ex-
pression in CAT CAR transduced T cells compared to FMC63 CAR transduced T
cells 10 days following CAR infusion in a different in vivo tumour rescue model,
where CAR T cells were infused 24 hours following Raji tumour cell infusion and
disease had been eliminated for several days before the timepoint at which PD-1
expression was analysed.
The hierarchical loss of effector function describes the loss of the ability of
virus-specific CD8+ T cells to produce TNF-α and IL-2. Interestingly, the ability to
produce IFN-γ is maintained and more resistant to inactivation [200]. In vitro we
had already shown a significantly greater production of TNF-α (Mean concentration
± SEM: CAT CAR T cells: 750.7± 103.3 pg/ml, FMC CAR T cells: 292.1± 36.51
pg/ml) and a trend towards greater production of IL-2 by CAT CAR transduced T
cells (Mean concentration ± SD CAT CAR T cells: 11156 ± 2777 pg/ml, FMC63
CAR T cells: 5501 ± 1285 pg/ml) (Fig. 4.8), as discussed in section 4.2.4.1. These
results were obtained after a relative short exposure of 48 hours to irradiated anti-
gens and can therefore not be explained as a result of reduced exhaustion of CAT
CAR transduced T cells compared to FMC63 transduced T cells. Interestingly how-
ever, our findings in vivo seemingly reflect these differences indicating that CAT
CAR T cells at the tumour site show a greater ability to express TNF-α and again
a trend towards greater expression of IL-2 as well, 12 days following transfer to
tumour bearing hosts.
Several studies have suggested that the expansion and differentiation program
is imprinted shortly after antigenic stimulation [181]. A typical CD8 T cell response
consists of three main developmental stages: effector cell expansion and differen-
tiation; effector cell contraction; and stabilization and maintenance of the memory
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cell population [183]. IL-7 is involved in maintaining memory populations after the
clearance of antigen, and IL-7Rα signalling has an important function in T cell sur-
vival by increasing the expression of anti-apoptotic molecules (Bcl-2 and Bcl-XL)
and by maintaining glycolysis and respiration levels in T cells through activation
of multiple signal transduction pathways [183]. Van Leeuwen et al. describe that
in chronic infections IL-7Rα+ T cells express higher levels of Bcl-2 show a supe-
rior recall response and enhanced proliferation in response to homeostatic signals
[181]. Interestingly when we investigated IL-7Rα expression (CD127) on CAR
transduced T cells 15 days following infusion in vivo, we showed a significantly
greater proportion of IL-7Rα+ CAT CAR transduced T cells, as well as signifi-
cantly higher expression levels. This directly correlated with an upregulation of the
anti-apoptotic molecule Bcl-2, akin to results previously reported in chronic infec-
tions [183]. We speculate that the higher levels of Bcl-2 in CAT CAR T cells may
contribute to their expansion and persistence by preventing apoptosis and AICD.
The downstream mechanisms by which signalling through the CAT CAR results in
greater upregulation of Bcl-2 compared to signalling through FMC63 are clearly of
great interest and merit further investigation.
6.2.3 Directions for further investigation
Activation of mTOR-dependent pathways regulates the differentiation of CD8+ and
CD4+ T cell subsets [202]. T cell stimulation and expansion induces a shift from ox-
idative respiration to aerobic glyocolysis [203]. This shift in the metabolic balance
is regulated by the mTOR kinase pathway, through the MTORC1 and MTORC2
complexes. Upon T cell activation mTORC1 kinase activity is triggered leading
to cell growth, expansion and differentiation of effector cells, resulting in reduced
expression of CD62L (a lymph node homing molecule) and a switch to aerobic
glycolysis [203]. Corse et al. observed attenuation at the level of intracellular sig-
nalling intermediates associated with Akt kinase activation and cytokine signalling,
depending on TCR affinity. Upon stimulation high affinity TCR T cells were pos-
itive for pAKT, indicating greater activity of mTORC2 [185]. It has been shown
that increased mTORC1 activity promotes earlier tumour infiltration and enhanced
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disease clearance in a murine EL4-NP thymoma model [203]. However these ac-
tivated T cells show reduced persistence, which has been reported to be essential
for effective clinical activity of CAR T cells [73, 74]. When mTORC1 activity
was completely inhibited, the F5+ TCR T cells showed a reduced effector response
and reduced tumour infiltration as a result of a quiescent state, as well as high ex-
pression levels of CD62L and CD127, markers associated with central memory
differentiation. Complete inhibition of mTORC1 activity, can lead to anergic T
cells incapable of generating effector cells either during the primary response or
recall [203]. When investigating the specific effect of mTORC2 on CD8+ T cell
memory, Pollizzi et al. showed that T cell deficient for mTORC2 showed equiva-
lent or enhanced cytotoxicity and accumulation of antigen specific T cells, where
mTORC1 deficient mice were unable to get activated or proliferate, like indicated
earlier [202, 203]. Interestingly however, was the upregulation of CD127 and Bcl2
in mTORC2 deficient cells, through FOXO-induced expression, which directly cor-
related to improved persistence and a better recall response compared to wild type.
Thus, mTORC2 deficient mice generated a robust effector response, whilst simulta-
neously upregulating markers associated with increased T cell fitness and reduced
apoptosis. We hypothesize that given the increased expression levels of CD127 and
Bcl2 on CAT CAR transduced T cells as well as their increased functionality and
accumulation in vivo, that mTORC1 and mTORC2 are differentially activated in
CAT compared to FMC63 transduced T cells, potentially showing a greater activ-
ity of mTORC2 in FMC63 transduced T cells. Important for an effective CAR T
cell response is the differentiation of effector cells while at the same time enabling
self-renewal needed for long-term memory. Rapamycin inhibits mTOR activity and
has been shown to enhance antitumour CD8+ activity as well as increased persis-
tence of tumour-infiltrating lymphocytes [204]. When given at low dose, the initial
expansion of effector cells is maintained, but persistence is improved both by in-
creasing the number of effector memory precursors in the expansion phase, as well
as promoting central memory T cells during the contraction phase [204] and both
Velica et al. and Pollizzi et al. showed that temporarily blocking mTOR activity
6.2. Delineating the impact of binding-domain affinity on CAR T-cell function157
promotes the generation of functional memory T cells. We suggest that future ex-
periments inhibiting the mTOR activity in FMC63 CAR transduced T cells, and
selective inhibition of mTORC2 activity specifically may improve FMC63 CAR T
cell functionality, accumulation and persistence in vivo further unravelling the effect
of CAR T cell affinity on intracellular signalling pathways.
In early correlative studies of patients treated with TCR-engineered cells, the
ability of the engineered cells to function upon tumour encounter immediately ex
vivo was the single difference found between responders and non-responders. Both
groups had high levels of engineered T cell in circulation one month after treatment,
however only T cells from patients who showed a clinical response were responsive
to ex vivo tumour exposure, as identified by IFN-γ and IL-2 production [205]. To
further investigate the fitness of FMC63 and CAT CAR transduced T cells we pro-
pose ex vivo proliferation experiments and cytokine response experiments of CAR T
cells following tumour clearance in vivo. Furthermore, secondary transfer of CAR
T cell effectors should provide essential further insight. We hypothesize, given the
reduced number of FMC63 CAR T cells and a reduced capacity to produce cy-
tokines following antigen specific stimulation in vivo, which may be a reflection
of AICD and exhaustion, that FMC63 CAR transduced T cells would show an im-
paired proliferative response following secondary stimulation ex vivo as well as a
reduced cytokine response. It has been shown in the case of chronic antigen expo-
sure that virus-specific CD8+ T cells generated during chronic LCMV infection fail
to persist when adoptively transferred to naive uninfected mice, indicating possi-
ble defects in memory T cell homeostasis [206]. Unfortunately we were unable to
study persistence of CAR T cells in vivo, due to development of xeno-GvHD so that
prolonged experiments were not feasible. Our aim to re-challenge after successful
tumour elimination, examining the memory recall responses would require higher
doses of CAR T cells, as we did not establish disease clearance. Consequently, to
reduce the total number of total T cells infused we propose to use sorted populations
of CAR T cells in future experiments, thereby reducing the risk for xeno-GvHD. We
would expect this memory recall response to be impaired in FMC63 CAR T cells
6.2. Delineating the impact of binding-domain affinity on CAR T-cell function158
again as a result of exhaustion as well as potential differences in mTOR activity
[199, 202, 203].
To identify the molecular mechanisms underlying these functional effects thor-
ough investigation of signalling pathways downstream as well as global gene ex-
pression and activatory/inhibitory membrane receptors on human CD8+ T cells en-
gineered with CARs of incremental affinity will likely lend further understanding
into these mechanisms, as well as the biochemistry of CAR T cell activation in
general. The functional impairment of high avidity T cells in the presence of high
levels of antigen has been described to be related to enhanced activity of down-
stream sarcoma homology domain 2 phosphatase (SHP)1 [21]. SHP-1 phosphatase
may represent an important regulatory molecule in CD8+ T cells with incremental
affinity TCR variants. Strikingly, is has been shown that SHP-1 mediates a gradual
functional inhibition of CD8+ T cells, along with TCR-binding affinity, indepen-
dently of PD-1 involvement [192]. In addition, in T cells expressing expressing
TCRs with supraphysiological affinities ZAP-70 phosphorylation declined rapidly
and substantially following specific stimulation and a transient and rapid loss of
ERK1/2 phosphorylation following TCR stimulation was observed [192]. The as-
sessment of SHP1 , the activation levels of ZAP-70, a proximal activatory molecule
of TCR signalling and of the distal MAPK family members ERK1/2 is therefore
warranted. Gene expression profiles specific for exhausted T cells [119] and spe-
cific for the metabolic profile of T cells [122] have been described and could be
further exploited in the comparison of FMC63 and CAT CAR transduced cells as
well.
Lastly, the difference in motility and number of (contemporaneous) interac-
tions of CAT CAR transduced T cells provides a new direction of research in CAR
T cell biology, particularly relevant when targeting solid cancers. Actin remodelling
is an important component of immunological synapse formation and cytoskeleton
organization is tightly integrated with T cell activation and signalling [17]. The
adhesion and signal transduction depend on physical forces exerted by actin cy-
toskeletal dynamics. Immunological synapse (IS)-associated signalling molecules
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are physically linked to actin filaments; conformational changes exerted by these
forces are needed for full T cell activation [18]. Research by Bousso’s lab, in-
vestigating T cell motility in relation to TCR affinity, has shown that extracellular
calcium influx is involved in T-cell motility arrest during antigen recognition. They
observed robust calcium elevation in T cells stimulated with high affinity protein
complexes, but low affinity protein complexes resulted in little or no signal[207].
They show that low-affinity antigen induces a calcium-independent partial deceler-
ation, whereas high-affinity antigen provides an additional calcium-dependent sig-
nal that facilitates complete T-cell arrest. Furthermore, LAT protein that has been
shown to be enriched in the uropod of migrating T cells was differentially organised
in high affinity TCR reactions compared to low affinity, being more at the front of
the low affinity T cells, in contrast to restriction in the uropod region of high affinity
T cells. Altogether, these experiments establish the existence of distinct cellular
organization patterns that differ in the presence of low-affinity peptide compared
with steady-state conditions, strongly suggesting that a switch in the mode of mi-
gration underlies T cell motility. Their results suggest that TCR engagement acts
by two mechanisms to promote T cell deceleration: binding to pMHC may pro-
mote adhesion and switching of migration mode, whereas strong intracellular TCR
signals are required for full arrest. Deceleration induced by low-affinity antigenic
complexes was dependent on TCR engagement, but appeared largely independent
of downstream TCR signals[207]. It is therefore possible that TCR signalling in-
terferes with molecular motors that impact T cell motility. Little is known about
CAR T cell synapse formation. Neeson et al. have shown reduced accumulation of
LFA-1 integrin, mediating adhesion between T cells and APCs, in the synapse of
CAR T cell [125]. There have been no further studies however. Having observed
such distinct kinetic profiles between FMC63 and CAT CAR transduced cells, we
hypothesize that there could be differences in synapse formation depending on CAR
T cell affinity, which may affect actin remodelling and adhesion. However, using
live cell imaging we saw no difference in effector:target interaction dwell time be-
tween FMC63 and CAT CAR transduced T cells. We therefore propose that a longer
6.2. Delineating the impact of binding-domain affinity on CAR T-cell function160
t1/2 of CAR transduced cells may result in differences in downstream signalling and
impair T cell recovery, affecting switching of the migration mode and resulting in a
full T cell arrest, which necessitates further studies.
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6.3 Final conclusion
We have developed a novel CD19-CAR which confers enhanced cytotoxicity and
proliferative responses compared to existing CD19-CARs. Our work indicates that
the kinetics of scFv binding significantly impact the functional avidity of CAR-
transduced T cells, providing important implications for the development of future
CARs. It is possible that the improved functional avidity associated with the off-rate
of the CAR binding domain is a feature specific for CD19 as the antigen, as it has
previously been asserted that a lower affinity CAR results in diminished functional
avidity when a different antigen was targeted[151, 152]. However, we rationalize
that, analogous to the natural TCR and as indicated by previous work on bi-specific
T-cell engagers, a lower overall binding affinity for a target might be mitigated by
a relatively faster off-rate in the setting of a constant on-rate, allowing for serial
triggering and rapid regaining of quiescence because of more rapid termination of
immunoreceptor signalling. Collectively, these data emphasize the potential impact
of CAR-binding affinity in relation to T cell activation and highlight the need to
carefully assess CAR affinity/avidity in relation to its functional efficacy. In other
words, one should separately scrutinize the two determinants of affinity, the on- and
off-rate in determining optimal CAR binding characteristics. We believe this to be
of particular relevance when target antigen expression levels are low and further
work is needed to investigate this effect on low-expressed antigens. Most impor-
tantly, clinical evaluation of CAT-CAR is being undertaken in the CARPALL trial
(clinicaltrials.gov, NCT02443831), in which we aim to specifically study the im-
pact of using this low affinity CD19 CAR on disease response, T cell expansion and
persistence.
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